var title_f6_18_6432="CNS lymphoma flow study";
var content_f6_18_6432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow cytometry of cerebrospinal fluid demonstrates lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This flow cytometry study of a sample of lymphocytes obtained from the cerebrospinal fluid of a patient with suspected lymphoma shows a population of B-lymphocytes (green color, asterisk) which stains positive for kappa light chains (Y axis) and positive for CD19 expression (x axis). This same CD19 positive cell population stained negative for lambda light chain expression (not shown here), identifying this as a monoclonal population of lymphocytes, and suggesting that these cells represent involvement of the neuraxis with lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6432=[""].join("\n");
var outline_f6_18_6432=null;
var title_f6_18_6433="Palpation of palmar fascia";
var content_f6_18_6433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the palmar fascia for nodularity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hand is placed in the palm up position. Each of the four digits are passively stretched in extension, noting any differences in flexibility and tendon scarring between the fingers. Next, the tendons are palpated for thickening or nodularity along their course through the palm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6433=[""].join("\n");
var outline_f6_18_6433=null;
var title_f6_18_6434="Patient information: Hypoparathyroidism (The Basics)";
var content_f6_18_6434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17220\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"         Thyroid and parathyroid glands",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/54/3938\">",
"         Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/54/15203\">",
"         Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hypoparathyroidism (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hypoparathyroidism-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9646588\">",
"      <span class=\"h1\">",
"       What is hypoparathyroidism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hypoparathyroidism is a rare condition of the parathyroid glands in your neck (",
"      <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"       figure 1",
"      </a>",
"      ). These glands make a hormone that helps control the amount of calcium in the blood. The hormone is called &ldquo;parathyroid hormone,&rdquo; or &ldquo;PTH.&rdquo;",
"     </p>",
"     <p>",
"      You get hypoparathyroidism when you have too little PTH in your body. This causes the levels of calcium in your blood to get too low.",
"     </p>",
"     <p>",
"      Neck surgery on the thyroid or parathyroid glands or major surgery for head and neck cancer is the most common cause of hypoparathyroidism. After this surgery, some people have hypoparathyroidism that lasts only a short time. Other people have hypoparathyroidism for the rest of their lives, but this is less common. Other conditions can also cause hypoparathyroidism. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9646603\">",
"      <span class=\"h1\">",
"       What are the symptoms of hypoparathyroidism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms are different depending on the cause of hypoparathyroidism.",
"     </p>",
"     <p>",
"      People who develop hypoparathyroidism after neck surgery can have the following symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tingling in the hands or feet, or around the mouth",
"       </li>",
"       <li>",
"        Unusual muscle movements, such as jerking, twitching, or spasms",
"       </li>",
"       <li>",
"        Muscle cramps",
"       </li>",
"       <li>",
"        Feeling tired, irritable, anxious, or depressed",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with long-lasting hypoparathyroidism caused by other medical conditions can have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eye problems, especially cataracts",
"       </li>",
"       <li>",
"        Dry, thick skin",
"       </li>",
"       <li>",
"        Coarse hair that breaks easily and can fall out, causing bald spots &nbsp;",
"       </li>",
"       <li>",
"        Fingernails that break easily, with ridges that go from left to right",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9646618\">",
"      <span class=\"h1\">",
"       Is there a test for hypoparathyroidism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A doctor or nurse should be able to tell if you have hypoparathyroidism by doing blood tests to measure your calcium and PTH levels. He or she might also test the levels of other minerals and vitamin D in your blood. You might have tests to measure calcium and magnesium levels in your urine. &nbsp;",
"     </p>",
"     <p>",
"      Long-lasting hypoparathyroidism that is not treated can cause calcium to build up in the brain. Your doctor might order an X-ray of your head to look for calcium buildups. If the X-ray does not show anything, but your doctor still thinks you might have hypoparathyroidism, he or she might order an imaging test called a &ldquo;CT scan.&rdquo; This test creates a better image of your brain than an X-ray does. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9646632\">",
"      <span class=\"h1\">",
"       How is hypoparathyroidism treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Taking calcium and vitamin D supplements is the main treatment for hypoparathyroidism. Your doctor might also give you medicines, such as diuretics (water pills) to prevent too much calcium from leaving your body in your urine.",
"     </p>",
"     <p>",
"      When you start taking supplements, your doctor or nurse will test your blood and urine every week. The tests will show if your calcium level is coming back to normal. Your doctor or nurse can also check that the supplements are not causing other health problems. When your calcium level is normal again, you only need blood and urine tests every 3 to 6 months. &nbsp;",
"     </p>",
"     <p>",
"      If you have permanent hypoparathyroidism, you will need to take supplements for life. If your parathyroid glands stop working for a short time, such as after surgery, you might only need treatment until the glands start working again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9646647\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk to your doctor, nurse, or midwife about your hypoparathyroidism. He or she will measure your levels of calcium, PTH, and vitamin D while you are pregnant and after you give birth. Testing is especially important in the later months of pregnancy and while you are nursing your baby. Your doctor, nurse, or midwife can help you get the right supplements and any medicines you need to have a healthy baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9646662\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with hypoparathyroidism are able to live normal lives. If your doctor or nurse gives you supplements or medicines, take them the way he or she tells you to. Make sure you get any tests you need on time. If you have questions, ask your doctor or nurse. He or she will watch for problems and treat them if they happen.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9646677\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/18/6434?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17220 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6434=[""].join("\n");
var outline_f6_18_6434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9646588\">",
"      What is hypoparathyroidism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9646603\">",
"      What are the symptoms of hypoparathyroidism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9646618\">",
"      Is there a test for hypoparathyroidism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9646632\">",
"      How is hypoparathyroidism treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9646647\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9646662\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9646677\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"      Thyroid and parathyroid glands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_18_6435="Paraaortic node dissection3";
var content_f6_18_6435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Completed right paraaortic node dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6435=[""].join("\n");
var outline_f6_18_6435=null;
var title_f6_18_6436="Erythema migrans - early disseminated Lyme";
var content_f6_18_6436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early disseminated Lyme disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple lesions of erythema migrans are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6436=[""].join("\n");
var outline_f6_18_6436=null;
var title_f6_18_6437="Liver biopsy in a child with indeterminate acute liver failure";
var content_f6_18_6437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Liver biopsy in a child with indeterminate acute liver failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a liver biopsy in a child with acute liver failure of indeterminate etiology, with falling ALT (1250 IU/L to 275 IU/L), rising total bilirubin (12.5 mg/dL to 25 mg/dL) and rising prothrombin time (rising from 20 to 26 seconds). Histology reveals a dense infiltrate dominated by lymphocytes, but with scattered neutrophils and eosinophils, and with hepatic necrosis and biliary damage.",
"    <br/>",
"    (A) Low power view.",
"    <br/>",
"    (B) High power view.",
"    <div class=\"footnotes\">",
"     ALT: alanine aminotransferase; IU: international unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Squires RH, Alonso EM. Acute liver failure in children. In: Liver Disease in Children, 4th ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2012. Copyright &copy; 2012 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6437=[""].join("\n");
var outline_f6_18_6437=null;
var title_f6_18_6438="Echocardiographic evaluation of prosthetic heart valves";
var content_f6_18_6438=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Echocardiographic evaluation of prosthetic heart valves",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6438/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6438/contributors\">",
"     Elyse Foster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6438/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6438/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6438/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6438/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6438/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/18/6438/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 20, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delineation of normal prosthetic valve function is often possible with transthoracic echocardiography. Despite the prominent acoustic shadowing that accompanies mechanical prostheses, a Doppler signal that demonstrates normal transprosthetic flow velocity and flow duration is usually sufficient to exclude a stenotic valve. Exclusion of valvular regurgitation is often more difficult, especially for mechanical prostheses in the mitral position. As an example, one study of 170 patients who underwent surgery for valve dysfunction found that diagnostic errors, ie, findings on the echocardiogram that were not confirmed at surgery, occurred in 12 percent, and were primarily related to paravalvular regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transthoracic Doppler echocardiography provides important hemodynamic information with regard to prosthetic valve pressure gradients and is extremely useful in long-term follow-up. The \"normal gradient\" across a prosthetic valve depends upon the type, size, and position of the prosthesis as well as the cardiac output;",
"    <a class=\"external\" href=\"file://www.asecho.org/files/public/PVText.pdf\">",
"     guidelines",
"    </a>",
"    are available for the acceptable range of Doppler gradients encountered in properly functioning valves (",
"    <a class=\"graphic graphic_table graphicRef67758 \" href=\"UTD.htm?33/35/34355\">",
"     table 1",
"    </a>",
"    )[",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acoustic shadowing caused by the prosthetic material may limit transthoracic visualization of prosthetic leaflets, vegetations, abscesses, and thrombi. In addition, while prosthetic aortic valve regurgitation is usually well visualized on surface color Doppler imaging, prosthetic mitral regurgitation is frequently undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/4\">",
"     4",
"    </a>",
"    ]. As a result, transesophageal echocardiography (TEE) is the imaging method of choice when the transthoracic echocardiogram is technically inadequate or when there are borderline findings on the transthoracic echocardiogram in a patient in whom there is a strong clinical suspicion of malfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transthoracic echocardiography images anteriorly, and thus is usually sufficient for evaluation of aortic prostheses. However, since the atria are situated in the far field where resolution is low, they are shadowed by a mechanical mitral prosthesis. Since TEE images are taken from a position posterior to the heart, the atrial side of the mitral and tricuspid valves can be seen. On the other hand, transthoracic echocardiography demonstrates the ventricular side of the valve that lies in its near field, whereas TEE does not. Both methods may have difficulty with the evaluation of aortic prostheses, and the presence of mitral and aortic devices in the same patient may make the task of the echocardiographer more difficult. In most cases, however, both echocardiographic methods are complementary.",
"   </p>",
"   <p>",
"    The physician evaluating a prosthetic device with TEE should be aware of the range of abnormalities that are possible in these devices and should match those possibilities to the patient's presentation. Complications of prosthetic valves detected by TEE include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Paravalvular leak",
"     </li>",
"     <li>",
"      Endocarditis (",
"      <a class=\"graphic graphic_movie graphicRef58762 \" href=\"UTD.htm?40/16/41230\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef74517 \" href=\"UTD.htm?25/30/26082\">",
"       movie 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extrinsic interference of function (pannus, thrombus, vegetation) resulting in obstruction or regurgitation (",
"      <a class=\"graphic graphic_movie graphicRef64234 \" href=\"UTD.htm?30/38/31343\">",
"       movie 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ball variance",
"     </li>",
"     <li>",
"      Strut fracture and component escape",
"     </li>",
"     <li>",
"      Leaflet tears of bioprosthesis",
"     </li>",
"     <li>",
"      Leaflet",
"      <span class=\"nowrap\">",
"       calcification/stenosis",
"      </span>",
"      of bioprosthesis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of the TEE for evaluating the abnormalities associated with prosthetic valves will be reviewed here. The major complications encountered with these valves and the role of echocardiography in the evaluation of infective endocarditis are discussed fully elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"     \"Role of echocardiography in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PARAVALVULAR REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paravalvular regurgitation can arise from broken or dehisced sutures, from a poorly seated ring, or from endocarditis (dehiscence). Hemolysis is a common, but generally underappreciated, complication of these leaks, especially when they occur with a mitral valve prosthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. A TEE is required to detect paravalvular leakage and should routinely be performed when a patient with a prosthetic valve presents with severe anemia. Severe hemolysis can also occur after mitral valve repair, when regurgitation develops around the annuloplasty ring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H13#H13\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Malfunctioning cardiac valves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To recognize a paravalvular leak, multiplane TEE must be performed with a high color frame rate and middle range Nyquist limits (35 to 50",
"    <span class=\"nowrap\">",
"     cm/sec)",
"    </span>",
"    in several views from several angles outside the sewing ring [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/7\">",
"     7",
"    </a>",
"    ]. There should be a careful search for periprosthetic leaks around as much of the valve circumference as possible and an attempt made to define the extent of the regurgitation once it is identified. The origin of a periprosthetic leak may appear deceivingly narrow when it is related to disruption of a limited number of sutures. In some cases, these jets are seen inadvertently when one examines other structures, such as the interatrial septum.",
"   </p>",
"   <p>",
"    The most severe form of paravalvular regurgitation is seen when there is dehiscence of a substantial portion of the sewing ring [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/8\">",
"     8",
"    </a>",
"    ]. In this setting, there may be such severe regurgitation that the regurgitant flow is almost laminar. As in angiography, the sewing ring on echocardiography is seen to rock with each cardiac cycle; mobile echo densities representing the liberated suture material often can be visualized. Both the laminar flow and the rocking motion of the ring may elude the inexperienced echocardiographer, delaying recognition of this life threatening condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROSTHETIC VALVE OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When, in a newly symptomatic patient, there is an unexpected rise in transprosthetic gradient from a baseline determination or from established normal values for valves of that type and size, the possibility of progressive obstruction should be considered.",
"    <a class=\"external\" href=\"file://www.asecho.org/files/public/PVText.pdf\">",
"     Guidelines",
"    </a>",
"    are available that contain the acceptable range of Doppler gradients encountered in properly functioning valves (",
"    <a class=\"graphic graphic_table graphicRef67758 \" href=\"UTD.htm?33/35/34355\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Causes of obstruction include pannus ingrowth, thrombus, and vegetation. Clinical clues to this possibility include the age of the valve and the adequacy of anticoagulation. In a bioprosthesis or heterograft, the leaflets themselves may become calcified and immobile.",
"   </p>",
"   <p>",
"    Once there is a high suspicion of obstruction, TEE should be strongly considered for etiologic definition with both mechanical and bioprosthetic valves. Doppler TEE is the primary means to diagnose prosthetic aortic valve obstruction; hemodynamic cardiac catheterization is not routinely needed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the case of suspected aortic pannus, the distal end of the left ventricular outflow tract should be examined both with imaging and with color flow. Pannus tends to lie close to the valve ring and can be easily overlooked. There can be a prevalve jet that suggests pannus, which, on further searching with a variety of frequencies, angles, and gain settings, will be detected.",
"     </li>",
"     <li>",
"      In the mitral position, the same procedure should be followed. Finding a high grade of spontaneous contrast in the left atrium, with or without thrombi, or finding thrombus around the sewing ring in the setting of adequate anticoagulation should heighten suspicion of pannus formation. Thin fibrillar strands are also encountered on the mitral annulus and the left ventricular outflow tract. These structures are brightly reflective and highly mobile and may or may not be associated with a pathologic process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When a thrombus is present in the vicinity of the sewing ring and when obstruction is clinically plausible and suggested by Doppler imaging, consideration should be given to the use of thrombolysis or surgery (",
"    <a class=\"graphic graphic_movie graphicRef58762 \" href=\"UTD.htm?40/16/41230\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef74517 \" href=\"UTD.htm?25/30/26082\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64234 \" href=\"UTD.htm?30/38/31343\">",
"     movie 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Distinction between thrombus and pannus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common etiology for prosthetic valve obstruction is thrombus formation; pannus formation due to fibrous tissue ingrowth is far less common. In one surgical study of 112 obstructed mechanical valves, pannus formation was the underlying cause in 11 percent of valves, pannus formation in combination with thrombus was present in 12 percent, while thrombus alone was the etiology in the remaining cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/11\">",
"     11",
"    </a>",
"    ]. Though associated with modest morbidity and mortality, thrombolytic therapy is often an effective alternative to surgery for hemodynamic treatment of thrombus. Therefore, it is important to distinguish between these two causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H13#H13\">",
"     \"Complications of prosthetic heart valves\", section on 'Pannus formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiographic differentiation of pannus and thrombus may be difficult. In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombus tends to be mobile, somewhat less echo-dense, and associated with spontaneous contrast",
"     </li>",
"     <li>",
"      Pannus is highly echogenic, consistent with its fibrous composition, and is usually firmly fixed (minimal mobility) to the valve apparatus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to establish factors associated with the presence of thrombus, one study evaluated the findings on a preoperative TEE in 53 patients with an intraoperative diagnosis of pannus or thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/12\">",
"     12",
"    </a>",
"    ]. Predictors of thrombus or a mixed presentation (pannus and thrombus) included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mobile mass",
"     </li>",
"     <li>",
"      Attachment of mass to valve occluder",
"     </li>",
"     <li>",
"      Elevated gradients",
"     </li>",
"     <li>",
"      An international normalized ratio (INR) &le;2.5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with thrombus or a mixed presentation had one or more of these features. The prevalence of thrombus with &le;1, 2, and &ge;3 features was 14, 69, and 91 percent, respectively.",
"   </p>",
"   <p>",
"    Color flow aliasing with proximal acceleration of the flow jet in the vicinity of the mass may aid in the identification of pannus. In one study of 23 patients who presented with 24 obstructed valves, clinical, transthoracic, and TEE data were compared to pathology at surgery in order to determine the clinical and echocardiographic characteristics that differentiate thrombus from pannus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/13\">",
"     13",
"    </a>",
"    ]. Thrombus was established in 14 valves and pannus in 10. Pannus formation was more common in the aortic position. From the standpoint of echocardiography, thrombus was more likely to be associated with soft ultrasound density (92 versus 29 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROSTHETIC VALVE REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic regurgitation, the so-called seating puff of angiography, is universally encountered and dependent in degree on the type of prosthesis used. However, severe regurgitation may result from bioprosthetic valve degeneration, mechanical valve pannus, thrombus, or vegetation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physiologic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All mechanical valves exhibit some degree of obligatory regurgitation of up to 15 mL of blood [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/14\">",
"     14",
"    </a>",
"    ]. Seating regurgitation or \"closure backflow\" appears only briefly and is due to retrograde volume displacement as the valve leaflets close. This type of regurgitation is detected by highly sensitive color flow Doppler imaging on TEE. In addition, a certain amount of more prolonged \"leakage backflow\" regurgitation occurs after the valve closes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an evaluation of 136 mechanical prosthetic valves, TEE color Doppler imaging revealed regurgitant jets in 95 percent of the mitral prostheses and 44 percent of the aortic prostheses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast transthoracic echocardiography documented regurgitant jets in only 28 and 29 percent, respectively. The lower incidence of detected regurgitation in the aortic position may be explained by the shadowing of the left ventricular outflow tract in TEE imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normally functioning mechanical valves, such as the bileaflet St. Jude, usually have two to four centrally directed regurgitant jets. Features associated with these jets include a low intensity and only minimal penetration into the atrium, generally less than 3 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ]. The monodisc Medtronic-Hall valve has two jets, one of which is prominent and longer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Normally functioning bioprosthetic and heterografts are less likely to have these small regurgitant signals; when mild regurgitation is present, there is usually one central jet [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/16,21\">",
"     16,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathologic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic jets tend to be high velocity, central, intense, broad, and highly aliased; they tend to be eccentric, hugging the wall of the atrium (Coanda effect), penetrating to its roof, continuing around its perimeter and terminating where they began. The offending mass or tissue can usually be seen, but the actual locus of obstruction causing the regurgitation may not be visible.",
"   </p>",
"   <p>",
"    In contrast to mechanical valves, bioprostheses with leaflet degeneration may exhibit central pathologic regurgitation that is broad-based when severe. The bioprosthetic leaflets can usually be seen and are often thickened and calcified with possible perforation or disruption leading to a flail leaflet. Forward flow velocities measured by spectral Doppler may be increased due to the larger flow volume associated with regurgitation as well as concurrent obstruction.",
"   </p>",
"   <p>",
"    A review of 134 patients with a prosthetic valve attempted to derive echocardiographic indices of valvular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/22\">",
"     22",
"    </a>",
"    ]. The results suggested that a peak transmitral flow velocity exceeding 1.9",
"    <span class=\"nowrap\">",
"     m/sec",
"    </span>",
"    or a ratio of peak diastolic transmitral flow to left ventricular outflow tract velocity greater than 2.2 identifies prosthetic valve regurgitation (sensitivity 92 percent, specificity 78 percent) provided that the valve is not stenotic (pressure half-time less than 130 msec) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/22\">",
"     22",
"    </a>",
"    ]. On the other hand, a prosthetic valve with a peak inflow Doppler velocity of less than 1.9",
"    <span class=\"nowrap\">",
"     m/sec,",
"    </span>",
"    a ratio of peak diastolic transmitral flow velocity to left ventricular outflow velocity of less than 2.2, and a pressure half-time of less than 130 msec has a 98 percent chance of being normal (neither stenotic nor regurgitant).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REGURGITATION DUE TO STRUT FRACTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There had been considerable concern about Bjork-Shiley convexoconcave valves because of their low, but significant, incidence of strut fracture, leading to migration of the disk and rapid hemodynamic compromise. Fortunately, this uncommon occurrence has vanished due to the retirement of this valve. When it did occur, clinical deterioration was so rapid that diagnostic TEE could not be performed and survivors were taken directly to surgery based on clinical suspicion alone. The current generation of prosthetic valves over the past decade has been free of disk dislodgement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SYSTEMIC EMBOLI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a suspected cardiac cause for embolism, the source may be a thrombus from a nonobstructed prosthetic heart valve; TEE is helpful for establishing this diagnosis. In a series of 52 patients with a prosthetic heart valve who underwent TEE after a suspected systemic embolic event, 12 percent had a definitive prosthetic valve thrombus and 10 percent had fibrous strands on the valve, which were suggestive of thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6438/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/1\">",
"      Faletra F, Constantin C, De Chiara F, et al. Incorrect echocardiographic diagnosis in patients with mechanical prosthetic valve dysfunction: correlation with surgical findings. Am J Med 2000; 108:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/2\">",
"      Reisner SA, Meltzer RS. Normal values of prosthetic valve Doppler echocardiographic parameters: a review. J Am Soc Echocardiogr 1988; 1:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/3\">",
"      Khandheria BK. Transesophageal echocardiography in the evaluation of prosthetic valves. Cardiol Clin 1993; 11:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/4\">",
"      Cohen GI, Davison MB, Klein AL, et al. A comparison of flow convergence with other transthoracic echocardiographic indexes of prosthetic mitral regurgitation. J Am Soc Echocardiogr 1992; 5:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/5\">",
"      Dilip KA, Vachaspathy P, Clarke B, et al. Haemolysis following mitral valve repair. J Cardiovasc Surg (Torino) 1992; 33:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/6\">",
"      Smith RE, Berg D. Occult paravalvular leak in a clinically normal St. Jude's mitral valve presenting with life-threatening microangiopathic hemolytic anemia. J Cardiovasc Surg (Torino) 1991; 32:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/7\">",
"      Groundstroem K, Rittoo D, Hoffman P, et al. Additional value of biplane transoesophageal imaging in assessment of mitral valve prostheses. Br Heart J 1993; 70:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/8\">",
"      Akamatsu S, Ueda N, Terazawa E, et al. Mitral prosthetic dehiscence with laminar regurgitant flow signals assessed by transesophageal echocardiography. Chest 1993; 104:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/9\">",
"      Girard SE, Miller FA Jr, Orszulak TA, et al. Reoperation for prosthetic aortic valve obstruction in the era of echocardiography: trends in diagnostic testing and comparison with surgical findings. J Am Coll Cardiol 2001; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/10\">",
"      Lengyel M, Fuster V, Keltai M, et al. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. J Am Coll Cardiol 1997; 30:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/11\">",
"      Deviri E, Sareli P, Wisenbaugh T, Cronje SL. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 1991; 17:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/12\">",
"      Lin SS, Tiong IY, Asher CR, et al. Prediction of thrombus-related mechanical prosthetic valve dysfunction using transesophageal echocardiography. Am J Cardiol 2000; 86:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/13\">",
"      Barbetseas J, Nagueh SF, Pitsavos C, et al. Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. J Am Coll Cardiol 1998; 32:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/14\">",
"      Baumgartner, H, Czer, L, DeRobertis, M, et al. Normal regurgitation in mechanical valve prostheses: Impact on Doppler Studies. American College of Cardiology Learning Center Highlights 1992; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/15\">",
"      Baumgartner H, Khan S, DeRobertis M, et al. Color Doppler regurgitant characteristics of normal mechanical mitral valve prostheses in vitro. Circulation 1992; 85:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/16\">",
"      Mohr-Kahaly S, Kupferwasser I, Erbel R, et al. Regurgitant flow in apparently normal valve prostheses: improved detection and semiquantitative analysis by transesophageal two-dimensional color-coded Doppler echocardiography. J Am Soc Echocardiogr 1990; 3:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/17\">",
"      Karalis DG, Chandrasekaran K, Ross JJ Jr, et al. Single-plane transesophageal echocardiography for assessing function of mechanical or bioprosthetic valves in the aortic valve position. Am J Cardiol 1992; 69:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/18\">",
"      Lange HW, Olson JD, Pedersen WR, et al. Transesophageal color Doppler echocardiography of the normal St. Jude Medical mitral valve prosthesis. Am Heart J 1991; 122:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/19\">",
"      Flachskampf FA, O'Shea JP, Griffin BP, et al. Patterns of normal transvalvular regurgitation in mechanical valve prostheses. J Am Coll Cardiol 1991; 18:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/20\">",
"      Hixson CS, Smith MD, Mattson MD, et al. Comparison of transesophageal color flow Doppler imaging of normal mitral regurgitant jets in St. Jude Medical and Medtronic Hall cardiac prostheses. J Am Soc Echocardiogr 1992; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/21\">",
"      Chen YT, Kan MN, Chen JS, et al. Detection of prosthetic mitral valve leak: a comparative study using transesophageal echocardiography, transthoracic echocardiography, and auscultation. J Clin Ultrasound 1990; 18:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/22\">",
"      Fernandes V, Olmos L, Nagueh SF, et al. Peak early diastolic velocity rather than pressure half-time is the best index of mechanical prosthetic mitral valve function. Am J Cardiol 2002; 89:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6438/abstract/23\">",
"      Shiran A, Weissman NJ, Merdler A, et al. Transesophageal echocardiographic findings in patients with nonobstructed prosthetic valves and suspected cardiac source of embolism. Am J Cardiol 2001; 88:1441.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5333 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-504D3CBC15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6438=[""].join("\n");
var outline_f6_18_6438=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PARAVALVULAR REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROSTHETIC VALVE OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Distinction between thrombus and pannus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROSTHETIC VALVE REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physiologic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathologic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REGURGITATION DUE TO STRUT FRACTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SYSTEMIC EMBOLI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5333\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5333|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/16/41230\" title=\"movie 1\">",
"      TEE prosthetic mitral valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?25/30/26082\" title=\"movie 2\">",
"      TEE mechanical mitral valve vegetations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?30/38/31343\" title=\"movie 3\">",
"      TEE LA and prosthetic MV thrombus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5333|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/35/34355\" title=\"table 1\">",
"      Normal echocardiography values for prosthetic mitral valves",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_18_6439="Mycology, pathogenesis, and epidemiology of Fusarium infection";
var content_f6_18_6439=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mycology, pathogenesis, and epidemiology of Fusarium infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6439/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6439/contributors\">",
"     Marcio Nucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6439/contributors\">",
"     Elias Anaissie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6439/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6439/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6439/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6439/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/18/6439/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species cause a broad spectrum of infections in humans including superficial infections, such as keratitis and onychomycosis, as well as locally invasive and disseminated infections; invasive and disseminated infections occur almost exclusively in severely immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/1\">",
"     1",
"    </a>",
"    ]. Fusarium species may also cause allergic diseases such as sinusitis in immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/2\">",
"     2",
"    </a>",
"    ], and mycotoxicosis following ingestion of food contaminated by toxin-producing Fusarium species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/3\">",
"     3",
"    </a>",
"    ]. Fusarium species are also important plant pathogens that cause various diseases on cereal grains [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/3\">",
"     3",
"    </a>",
"    ], and occasionally cause infection in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mycology, pathogenesis, and epidemiology of fusariosis will be reviewed here. The clinical manifestations, diagnosis, treatment, and prevention of fusariosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link\">",
"     \"Treatment and prevention of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYCOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species are widely distributed in soil, subterranean and aerial plant parts, plant debris, and other organic matter [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/3\">",
"     3",
"    </a>",
"    ]. They are also present in water worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516901989\">",
"    <span class=\"h2\">",
"     Growth in vitro",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species grow rapidly on many media that do not contain cycloheximide, which inhibits its growth. On potato dextrose agar, Fusarium species produce white-, lavender-, pink-, salmon-, or gray-colored colonies with velvety or cottony surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516902309\">",
"    <span class=\"h2\">",
"     Microscopic appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopically, the hyphae of Fusarium in tissue resemble those of Aspergillus species, with septate hyaline hyphae 3 to 8 microns in diameter that typically branch at acute angles (",
"    <a class=\"graphic graphic_picture graphicRef69801 \" href=\"UTD.htm?20/16/20738\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74308 \" href=\"UTD.htm?23/33/24080\">",
"     picture 2",
"    </a>",
"    ). Adventitious sporulation, which is the ability to sporulate in tissue and blood, may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/7\">",
"     7",
"    </a>",
"    ]; the identification of hyphal and yeast-like structures in the same specimen is highly suggestive of fusariosis in high-risk patients.",
"   </p>",
"   <p>",
"    In cultures, the production of both fusoid macroconidia (hyaline, multicellular, banana-like clusters with foot cells at the base) (",
"    <a class=\"graphic graphic_picture graphicRef72385 \" href=\"UTD.htm?25/6/25701\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61073 \" href=\"UTD.htm?7/27/7602\">",
"     picture 4",
"    </a>",
"    ), and microconidia (hyaline, unicellular, ovoid to cylindrical) are characteristic of the genus Fusarium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516901982\">",
"    <span class=\"h2\">",
"     Species identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic appearance of Fusarium macroconidia can be used for identification (",
"    <a class=\"graphic graphic_picture graphicRef72385 \" href=\"UTD.htm?25/6/25701\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61073 \" href=\"UTD.htm?7/27/7602\">",
"     picture 4",
"    </a>",
"    ), but species identification is difficult and often requires molecular methods [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19276811\">",
"    <span class=\"h2\">",
"     Species prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 100 species of Fusarium have been identified, but only a few cause infections in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/10\">",
"     10",
"    </a>",
"    ]. Fusarium solani is the most frequent cause of invasive disease (in approximately half of all cases), followed by F. oxysporum, F. moniliforme (previously F. verticillioides), and F. proliferatum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/11\">",
"     11",
"    </a>",
"    ]. Other species that rarely cause infections in humans include F. dimerum, F. chlamydosporum, F. sacchari, F. antophilum, and others. Fusarial keratitis is most commonly caused by F. solani [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/12\">",
"     12",
"    </a>",
"    ], whereas fusarial onychomycosis is most commonly caused by F. oxysporum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular phylogenetic studies have revealed that these pathogens comprise species complexes (eg, Fusarium solani",
"    <em>",
"    </em>",
"    complex, Fusarium oxysporum",
"    <em>",
"    </em>",
"    complex), which include at least 70 species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The clinical relevance of these species complexes remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524569980\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium spp cause invasive disease by angioinvasion and direct tissue destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. Fusarium species possess several virulence factors including mycotoxins, which suppress humoral and cellular immunity and can also cause allergic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/3\">",
"     3",
"    </a>",
"    ]. Fusarium spp also have the ability to adhere to prosthetic material [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/3\">",
"     3",
"    </a>",
"    ], and to produce proteases and collagenases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/18\">",
"     18",
"    </a>",
"    ]. Fusarium solani is thought to be the most virulent Fusarium species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/19\">",
"     19",
"    </a>",
"    ]. Some Fusarium species produce mycotoxins that are destructive to crops and can cause human disease when ingested with heavily contaminated grains [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524570005\">",
"    <span class=\"h2\">",
"     Immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innate immunity plays a major role in the defense against Fusarium species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/20\">",
"     20",
"    </a>",
"    ]. Macrophages and neutrophils damage fusarial hyphae, and their effect is primed by interferon-gamma,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    , granulocyte-macrophage colony-stimulating factor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/21\">",
"     21",
"    </a>",
"    ], and interleukin (IL)-15 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/22\">",
"     22",
"    </a>",
"    ]. The effect of IL-15 is mediated by the release of IL-8 and by direct stimulation of hyphal damage. The role of toll-like receptors in the innate immune recognition of fungi is increasingly being recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/23\">",
"     23",
"    </a>",
"    ], and although little is known about fusariosis and toll-like receptors, this system is likely to be important in invasive fusariosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species cause a broad spectrum of infections in humans, including superficial, locally invasive, and disseminated infections. The clinical form of infection depends upon the immune status of the host and the portal of entry of the pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473991960\">",
"    <span class=\"h2\">",
"     Immunocompetent hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratitis and onychomycosis are the most common infections in immunocompetent patients. Other sites of infection have also been reported (",
"    <a class=\"graphic graphic_table graphicRef64555 \" href=\"UTD.htm?8/5/8285\">",
"     table 1",
"    </a>",
"    )",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/24-36\">",
"     24-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420413563\">",
"    <span class=\"h3\">",
"     Keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium spp are a common cause of fungal keratitis, which may develop following the traumatic introduction of Fusarium-contaminated soil or plant material or due to poor hygiene practices of soft contact lens wearers, particularly in patients using glucocorticoid eye drops. A large international outbreak of fusarial keratitis between 2004 and 2006 was linked to use of a specific contact lens solution (ReNu with MoistureLoc) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. The solution was not intrinsically contaminated. The fungicidal action of the solution was diminished, allowing Fusarium that had been introduced by the wearer while caring for his or her lenses to grow and contaminate the contact lens and the lens case. The solution was recalled in the United States in 2006, and rates of contact lens-associated Fusarium keratitis have declined since then [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of fungal keratitis caused by Fusarium species is highly variable and depends largely upon the geographic location. For example, the incidence ranges from 8 percent in India to 25 percent in Pennsylvania, 63 percent in Florida, and 75 percent in Tanzania [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/12,43,44\">",
"     12,43,44",
"    </a>",
"    ]. These variable rates are probably related to climate characteristics, with tropical and subtropical areas exhibiting the highest rates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H420413570\">",
"    <span class=\"h3\">",
"     Onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusarium species have been reported as agents of onychomycosis with increasing frequency among immunocompetent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] with variable rates reported from different regions. As an example, in a study from central Italy, fewer than 2 percent of cases of onychomycosis were caused by Fusarium spp [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/47\">",
"     47",
"    </a>",
"    ], compared with more than 8 percent in a study of onychomycosis cases from the Northeast region of Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473991967\">",
"    <span class=\"h2\">",
"     Immunocompromised patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524570268\">",
"    <span class=\"h3\">",
"     Portals of entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive fusariosis has been reported worldwide and may be acquired both in the community and in the hospital setting. The principal modes of infection are airborne or via direct inoculation at various sites (skin and others) of Fusarium-contaminated material, including water (",
"    <a class=\"graphic graphic_table graphicRef57202 \" href=\"UTD.htm?1/40/1676\">",
"     table 2",
"    </a>",
"    ). Preexisting skin breakdown or onychomycosis may facilitate direct introduction of Fusarium spp. Airborne infection results from the inhalation of fusarial conidia that in some circumstances can be associated with aerosolization of conidia from a water source [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524570275\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with compromised immune function are at high risk for invasive fusariosis, particularly in the setting of prolonged and profound neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe T cell immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/49\">",
"     49",
"    </a>",
"    ]. Unlike infection in normal hosts, fusariosis in the immunocompromised population is typically invasive and disseminated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/24\">",
"     24",
"    </a>",
"    ]. Among patients with hematologic malignancy, the infection predominates during periods of neutropenia, typically among patients with leukemia receiving induction chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Invasive fusariosis also occurs with an increased frequency among hematopoietic cell transplant recipients. A trimodal distribution of infection has been identified among allogeneic hematopoietic cell transplant (HCT) recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/51\">",
"     51",
"    </a>",
"    ]. The first peak occurs during the first 30 days following transplantation and is associated with neutropenia. Severe T cell immunodeficiency (but not neutropenia) is the major risk factor for fusariosis that develops after engraftment and which occurs at a median of 70 days after HCT, commonly in the setting of acute graft-versus-host disease (GVHD) and therapy with glucocorticoids. The third peak is observed &gt;1 year after HCT during treatment for extensive chronic GVHD. The overall incidence of fusariosis among HCT recipients is approximately 6 cases per 1000 patients and is lowest after autologous HCT (approximately 1.5 to 2 per 1000 patients). Following allogeneic HCT, the risk is lower in matched-related and matched-unrelated HCTs (approximately 2.5 to 5 per 1000 patients) compared with mismatched-related HCTs (20 per 1000 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of fusariosis is directly related to the patient&rsquo;s immune status, with high death rates in patients with persistent immunodeficiencies. In a series of 84 patients with fusariosis and an underlying hematologic malignancy, persistent neutropenia and recent glucocorticoid therapy were the only independent factors associated with poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link&amp;anchor=H5519506#H5519506\">",
"     \"Treatment and prevention of Fusarium infection\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Locally invasive Fusarium infections occur occasionally among solid organ transplant recipients, typically during the late post-transplant period; disseminated infections have been reported rarely in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6439/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of fusariosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fusarium species are important plant pathogens that cause various diseases on cereal grains, and occasionally cause infection in animals. In humans, Fusarium species cause a broad spectrum of infections including superficial infections such as keratitis and onychomycosis, as well as locally invasive and disseminated infections; invasive and disseminated infections occur almost exclusively in severely immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fusarium species are widely distributed in soil, subterranean and aerial plant parts, plant debris and other organic matter. They are also present in water. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mycology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microscopically, the hyphae of Fusarium in tissue resemble those of Aspergillus species, with septate hyaline hyphae 3 to 8 microns in diameter that typically branch at acute angles (",
"      <a class=\"graphic graphic_picture graphicRef69801 \" href=\"UTD.htm?20/16/20738\">",
"       picture 1",
"      </a>",
"      ). The production of both fusoid macroconidia (hyaline, multicellular, banana-like clusters with foot cells at the base) (",
"      <a class=\"graphic graphic_picture graphicRef72385 \" href=\"UTD.htm?25/6/25701\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61073 \" href=\"UTD.htm?7/27/7602\">",
"       picture 4",
"      </a>",
"      ),",
"      <strong>",
"      </strong>",
"      and microconidia (hyaline, unicellular, ovoid to cylindrical) are characteristic of the genus Fusarium. (See",
"      <a class=\"local\" href=\"#H516902309\">",
"       'Microscopic appearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The characteristic appearance of Fusarium macroconidia is used for identification (",
"      <a class=\"graphic graphic_picture graphicRef72385 \" href=\"UTD.htm?25/6/25701\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61073 \" href=\"UTD.htm?7/27/7602\">",
"       picture 4",
"      </a>",
"      ), but species identification is difficult and often requires molecular methods. (See",
"      <a class=\"local\" href=\"#H516901982\">",
"       'Species identification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 100 species of Fusarium have been identified, but only a few cause infections in humans. Fusarium solani is the most frequent cause of invasive disease (in approximately half of all cases), followed by F. oxysporum, F. moniliforme (previously F. verticillioides), and F. proliferatum. (See",
"      <a class=\"local\" href=\"#H19276811\">",
"       'Species prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fusarium species cause invasive disease by angioinvasion and direct tissue destruction. Innate immunity plays a major role in the defense against various molds, including Fusarium species. Macrophages and neutrophils damage fusarial hyphae, and their effect is primed by interferon-gamma,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      , granulocyte-macrophage colony-stimulating factor, and interleukin-15. (See",
"      <a class=\"local\" href=\"#H524569980\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fusarium species cause a broad spectrum of infections in humans, including superficial, locally invasive, and disseminated infections. The clinical form of infection depends upon the immune status of the host and the portal of entry of the pathogen (",
"      <a class=\"graphic graphic_table graphicRef64555 \" href=\"UTD.htm?8/5/8285\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with compromised immune function are at high risk for invasive fusariosis, particularly in the setting of prolonged and profound neutropenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe T cell immunodeficiency, such as in patients with hematologic malignancies receiving induction chemotherapy or hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H524570275\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/1\">",
"      Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/2\">",
"      Wickern GM. Fusarium allergic fungal sinusitis. J Allergy Clin Immunol 1993; 92:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/3\">",
"      Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/4\">",
"      Evans J, Levesque D, de Lahunta A, Jensen HE. Intracranial fusariosis: a novel cause of fungal meningoencephalitis in a dog. Vet Pathol 2004; 41:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/5\">",
"      Elvers KT, Leeming K, Moore CP, Lappin-Scott HM. Bacterial-fungal biofilms in flowing water photo-processing tanks. J Appl Microbiol 1998; 84:607.",
"     </a>",
"    </li>",
"    <li>",
"     Silveira FP, Queiroz-Telles F, Nucci M. Invasive mold infections. In: Diagnosis of fungal infections, Maertens JA, Marr KA (Eds), Informa Healthcare, 2007. p.171.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/7\">",
"      Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 1998; 109:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/8\">",
"      Healy M, Reece K, Walton D, et al. Use of the Diversi Lab System for species and strain differentiation of Fusarium species isolates. J Clin Microbiol 2005; 43:5278.",
"     </a>",
"    </li>",
"    <li>",
"     Fleming, RV, Anaissie, EJ. Hyalohyphomycosis - Infection due to hyaline moulds. In: Diagnosis and Treatment of Human Mycoses, Hospenthal, DR, Rinaldi, MG (Eds), Humana Press, Totowa 2008. p.201.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/10\">",
"      Alastruey-Izquierdo A, Cuenca-Estrella M, Monz&oacute;n A, et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805.",
"     </a>",
"    </li>",
"    <li>",
"     Torres HA, Kontoyiannis DP. Hyalohyphomycoses (Hyaline Moulds). In: Essentials of Clinical Mycology, Second edition, Kauffman C, Pappas PG, Sobel JD (Eds), Springer, New York 2011. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/12\">",
"      D&oacute;czi I, Gyetvai T, Kredics L, Nagy E. Involvement of Fusarium spp. in fungal keratitis. Clin Microbiol Infect 2004; 10:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/13\">",
"      Brilhante RS, Cordeiro RA, Medrano DJ, et al. Onychomycosis in Cear&aacute; (Northeast Brazil): epidemiological and laboratory aspects. Mem Inst Oswaldo Cruz 2005; 100:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/14\">",
"      Godoy P, Nunes E, Silva V, et al. Onychomycosis caused by Fusarium solani and Fusarium oxysporum in S&atilde;o Paulo, Brazil. Mycopathologia 2004; 157:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/15\">",
"      Ninet B, Jan I, Bontems O, et al. Molecular identification of Fusarium species in onychomycoses. Dermatology 2005; 210:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/16\">",
"      O'Donnell K, Sutton DA, Fothergill A, et al. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol 2008; 46:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/17\">",
"      Balajee SA, Borman AM, Brandt ME, et al. Sequence-based identification of Aspergillus, fusarium, and mucorales species in the clinical mycology laboratory: where are we and where should we go from here? J Clin Microbiol 2009; 47:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/18\">",
"      Kr&aacute;tk&aacute; J, Kov&aacute;cikov&aacute; E. The effect of temperature and age of strains of Fusarium oxysporum on its enzymatic activity. Zentralbl Bakteriol Naturwiss 1979; 134:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/19\">",
"      Mayayo E, Pujol I, Guarro J. Experimental pathogenicity of four opportunist Fusarium species in a murine model. J Med Microbiol 1999; 48:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/20\">",
"      Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol 2005; 129:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/21\">",
"      Gaviria JM, van Burik JA, Dale DC, et al. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999; 179:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/22\">",
"      Winn RM, Gil-Lamaignere C, Roilides E, et al. Effects of interleukin-15 on antifungal responses of human polymorphonuclear leukocytes against Fusarium spp. and Scedosporium spp. Cytokine 2005; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/23\">",
"      Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/24\">",
"      Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/25\">",
"      Rippon JW, Larson RA, Rosenthal DM, Clayman J. Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: three cases and review of the literature. Mycopathologia 1988; 101:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/26\">",
"      Kerr CM, Perfect JR, Craven PC, et al. Fungal peritonitis in patients on continuous ambulatory peritoneal dialysis. Ann Intern Med 1983; 99:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/27\">",
"      Flynn JT, Meislich D, Kaiser BA, et al. Fusarium peritonitis in a child on peritoneal dialysis: case report and review of the literature. Perit Dial Int 1996; 16:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/28\">",
"      Kurien M, Anandi V, Raman R, Brahmadathan KN. Maxillary sinus fusariosis in immunocompetent hosts. J Laryngol Otol 1992; 106:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/29\">",
"      Madhavan M, Ratnakar C, Veliath AJ, et al. Primary disseminated fusarial infection. Postgrad Med J 1992; 68:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/30\">",
"      Sander A, Beyer U, Amberg R. Systemic Fusarium oxysporum infection in an immunocompetent patient with an adult respiratory distress syndrome (ARDS) and extracorporal membrane oxygenation (ECMO). Mycoses 1998; 41:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/31\">",
"      Murray CK, Beckius ML, McAllister K. Fusarium proliferatum superficial suppurative thrombophlebitis. Mil Med 2003; 168:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/32\">",
"      Sturm AW, Grave W, Kwee WS. Disseminated Fusarium oxysporum infection in patient with heatstroke. Lancet 1989; 1:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/33\">",
"      Pflugfelder SC, Flynn HW, Jr., et al. fungal endophthalmitis. Ophthlamology 1988; 95:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/34\">",
"      Gabriele P, Hutchins RK. Fusarium endophthalmitis in an intravenous drug abuser. Am J Ophthalmol 1996; 122:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/35\">",
"      Jakle C, Leek JC, Olson DA, Robbins DL. Septic arthritis due to Fusarium solani. J Rheumatol 1983; 10:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/36\">",
"      Bourguignon RL, Walsh AF, Flynn JC, et al. Fusarium species osteomyelitis. Case report. J Bone Joint Surg Am 1976; 58:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/37\">",
"      Chang DC, Grant GB, O'Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006; 296:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/38\">",
"      Khor WB, Aung T, Saw SM, et al. An outbreak of Fusarium keratitis associated with contact lens wear in Singapore. JAMA 2006; 295:2867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/39\">",
"      Patel A, Hammersmith K. Contact lens-related microbial keratitis: recent outbreaks. Curr Opin Ophthalmol 2008; 19:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/40\">",
"      Saw SM, Ooi PL, Tan DT, et al. Risk factors for contact lens-related fusarium keratitis: a case-control study in Singapore. Arch Ophthalmol 2007; 125:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/41\">",
"      Bullock JD, Elder BL, Khamis HJ, Warwar RE. Effects of time, temperature, and storage container on the growth of Fusarium species: implications for the worldwide Fusarium keratitis epidemic of 2004-2006. Arch Ophthalmol 2011; 129:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/42\">",
"      Yildiz EH, Abdalla YF, Elsahn AF, et al. Update on fungal keratitis from 1999 to 2008. Cornea 2010; 29:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/43\">",
"      Tanure MA, Cohen EJ, Sudesh S, et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea 2000; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/44\">",
"      Rosa RH Jr, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in south Florida. Ophthalmology 1994; 101:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/45\">",
"      Guilhermetti E, Takahachi G, Shinobu CS, Svidzinski TI. Fusarium spp. as agents of onychomycosis in immunocompetent hosts. Int J Dermatol 2007; 46:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/46\">",
"      Hilmiolu-Polat S, Metin DY, Inci R, et al. Non-dermatophytic molds as agents of onychomycosis in Izmir, Turkey - a prospective study. Mycopathologia 2005; 160:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/47\">",
"      Romano C, Papini M, Ghilardi A, Gianni C. Onychomycosis in children: a survey of 46 cases. Mycoses 2005; 48:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/48\">",
"      Anaissie EJ, Kuchar RT, Rex JH, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/49\">",
"      Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/50\">",
"      Nucci M, Anaissie EJ, Queiroz-Telles F, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/51\">",
"      Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6439/abstract/52\">",
"      Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001; 32:1237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2426 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6439=[""].join("\n");
var outline_f6_18_6439=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H516901989\">",
"      Growth in vitro",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H516902309\">",
"      Microscopic appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H516901982\">",
"      Species identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19276811\">",
"      Species prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H524569980\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H524570005\">",
"      Immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473991960\">",
"      Immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H420413563\">",
"      - Keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H420413570\">",
"      - Onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H473991967\">",
"      Immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H524570268\">",
"      - Portals of entry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H524570275\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2426\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2426|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/16/20738\" title=\"picture 1\">",
"      Fusarium hyphae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/33/24080\" title=\"picture 2\">",
"      Fusarium hematoxylin and eosin stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/6/25701\" title=\"picture 3\">",
"      Fusarium macroconidia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/27/7602\" title=\"picture 4\">",
"      F solani microscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2426|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/5/8285\" title=\"table 1\">",
"      Clinical spectrum of fusariosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/40/1676\" title=\"table 2\">",
"      Portals of entry for fusariosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=related_link\">",
"      Clinical manifestations and diagnosis of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_18_6440="Common bile duct exploration";
var content_f6_18_6440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Common bile duct exploration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6440/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6440/contributors\">",
"     W Scott Melvin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6440/contributors\">",
"     Peter Muscarella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6440/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6440/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6440/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6440/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/18/6440/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25286312\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common bile duct (CBD) stones are identified in 10 to 15 percent of patients undergoing surgery for symptomatic cholelithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/1\">",
"     1",
"    </a>",
"    ]. CBD stones require extraction to avoid complications, such as acute suppurative cholangitis, obstructive jaundice, hepatic abscess, and acute pancreatitis.",
"   </p>",
"   <p>",
"    Traditionally, CBD stones were diagnosed with intraoperative cholangiography and treated with open CBD exploration. Advances in preoperative imaging technology such as magnetic resonance cholangiopancreatography (MRCP) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70104 \" href=\"UTD.htm?33/40/34447\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68630 \" href=\"UTD.htm?43/14/44256\">",
"     image 2",
"    </a>",
"    ) and endoscopic ultrasound (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78437 \" href=\"UTD.htm?18/33/18963\">",
"     image 3",
"    </a>",
"    ), as well as the development of endoscopic retrograde cholangiopancreatography (ERCP), and minimally invasive surgical techniques have allowed for less invasive and more accurate methods of identifying and treating CBD stones.",
"   </p>",
"   <p>",
"    This topic will review laparoscopic and open CBD exploration. The diagnosis and the endoscopic treatment of choledocholithiasis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25286320\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF CBD STONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with symptomatic cholelithiasis must be evaluated to avoid the complications of retained stones. Clinical findings suggestive of CBD stones include right upper quadrant pain with radiation to the back, jaundice, cholangitis, and pancreatitis.",
"   </p>",
"   <p>",
"    Transabdominal right upper quadrant ultrasonography and liver function tests are the initial studies of choice for patients with cholelithiasis. Elevated liver function tests, age &gt;55 years, and CBD dilation are all predictive of CBD stones and mandate further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/2\">",
"     2",
"    </a>",
"    ]. These results along with the clinical presentation can be used to stratify the risk of CBD stones prior to performing cholecystectomy. The probability of having CBD stones can then be used to plan appropriate intervention (",
"    <a class=\"graphic graphic_algorithm graphicRef66945 \" href=\"UTD.htm?26/3/26686\">",
"     algorithm 1",
"    </a>",
"    ). The preoperative evaluation of suspected choledocholithiasis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11839322\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR CBD EXPLORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exploration of the CBD should be performed in all patients in whom CBD stones have been identified and who are surgical candidates and have failed, or are not candidates for, endoscopic therapy. Percutaneous transhepatic cholangiography, electrohydraulic lithotripsy, and laser lithotripsy may be useful in a small number of selected patients who are not candidates for surgery or endoscopic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=see_link\">",
"     \"Percutaneous transhepatic cholangiography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11839696\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent should include a discussion of the risks, benefits, and alternatives of CBD exploration. The patient should be counseled regarding the possibility of bile duct leak, abscess, and retained stones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382386448\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected and confirmed CBD stones should be given perioperative antibiotics. A first- or second-generation cephalosporin is recommended within one hour of the incision (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Equipment",
"    </strong>",
"     Appropriate equipment should be readily available including 3 to 5 French (F) biliary Fogarty catheters, wire baskets, 0.0035 inch guidewire, balloon (8 mm outer diameter)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mechanical (7 to 12 F) dilators, 3 to 5 mm choledochoscope with 1.1 mm or larger working channel, loop ligatures, and T-tubes. Additional choledochoscopic equipment includes a separate light source, an adaptor to allow simultaneous irrigation via biopsy channel, second camera, second monitor, or picture-in-picture display with video switcher.",
"   </p>",
"   <p>",
"    <strong>",
"     Fluoroscopy &minus;",
"    </strong>",
"    Fluoroscopy support should be available for all patients undergoing cholecystectomy, and radiology should be contacted for a C-arm fluoroscope and appropriate support personnel as soon as the necessity for intraoperative cholangiography is identified.",
"   </p>",
"   <p>",
"    <strong>",
"     Deep venous thrombosis prophylaxis &mdash;",
"    </strong>",
"    For patients undergoing general anesthesia, primary prophylaxis for prevention of deep venous thrombosis, such as sequential compression devices, should be employed (",
"    <a class=\"graphic graphic_table graphicRef50947 \" href=\"UTD.htm?34/54/35693\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A surgical timeout should be performed with the entire operating room team (anesthesiologist, surgeon, nurse, scrub technician) to assure correct patient identity, intended operation, and the informed consent (",
"    <a class=\"graphic graphic_table graphicRef59666 \" href=\"UTD.htm?39/28/40395\">",
"     table 3",
"    </a>",
"    ). A preoperative checklist is a good way to assure that all safety issues have been addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H813094\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE CHOLANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a decision has been made to perform CBD exploration, intraoperative cholangiography may be performed to confirm the diagnosis and outline the biliary anatomy before the CBD exploration is undertaken. Although some surgeons perform routine intraoperative cholangiography before CBD exploration, we selectively perform intraoperative cholangiography based upon findings of elevated liver function tests, a dilated common bile duct (&gt;6 mm), or a history of pancreatitis. Patients who present with jaundice may be best evaluated preoperatively using ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The catheter for intraoperative cholangiography is placed after careful dissection achieves the critical view of safety (",
"    <a class=\"graphic graphic_figure graphicRef66207 \" href=\"UTD.htm?25/3/25649\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link&amp;anchor=H20#H20\">",
"     \"Laparoscopic cholecystectomy: Techniques\", section on 'Critical view of safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For laparoscopic intraoperative cholangiography, a clip is applied proximally across the cystic duct once it is well seen. Stay sutures may be placed on either side of the planned bile duct incision. An incomplete vertical ductotomy is created, taking care not to injure the posterior wall of the duct, and the contents of the duct are milked toward the ductotomy. A cholangiogram catheter (4 to 5 F) with a metal reinforced tip is inserted through a transabdominal 14-gauge angiocatheter that has been placed in the right upper quadrant and into the abdomen.",
"   </p>",
"   <p>",
"    The catheter is manipulated into the cystic duct with laparoscopic instruments. There are cholangiogram catheters available on the market that secure the catheter and occlude the duct after placement either via grasping jaws or an inflatable balloon. Alternatively, a clip or a cholangiogram clamp can be loosely applied around the duct with the catheter. Placement of a hydrophilic guidewire through the cholangiogram catheter facilitates placement of instruments for CBD stone extraction and dilatation of the cystic duct with balloon catheters or mechanical dilators if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The position and seal of the catheter should be first tested with injection of saline. The saline and water-soluble contrast fluid and tubing must be free of bubbles before performing the cholangiogram, since bubbles can create filling defects which can be confused for stones.",
"   </p>",
"   <p>",
"    Contrast is then injected under continuous fluoroscopic visualization with a 1:1 dilution of water-soluble contrast and water. The images should be evaluated for the length of the cystic duct and the junction with the CBD, the size of the CBD, free flow of contrast into the duodenum, the intra and extrahepatic biliary anatomy, and the presence of filling defects. If the contrast does not flow freely into the duodenum, administration of sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    is sometimes helpful in relaxing the sphincter of Oddi.",
"   </p>",
"   <p>",
"    Proximal visualization of the bile ducts must also be confirmed, and techniques to facilitate this include administration of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (to contract the sphincter of Oddi), positioning the patient in steep Trendelenburg, and application of pressure to the distal bile duct with a laparoscopic instrument. Misplacement of the catheter in the CBD should be considered when the proximal biliary tree cannot be visualized. Findings on cholangiography that are suggestive of CBD stones include dilated bile ducts, filling defects, or failure of contrast flow into the duodenum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81939 \" href=\"UTD.htm?10/29/10707\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25286327\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACHES FOR CBD EXPLORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic CBD exploration, open CBD exploration, and postoperative ERCP with stone removal are all options for the treatment of CBD stones identified by intraoperative cholangiography. In experienced hands, laparoscopic CBD exploration has a success rate of over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/6\">",
"     6",
"    </a>",
"    ]. The choice of procedure should be guided by patient-specific considerations, training and experience of the surgeon, and available endoscopic expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25286334\">",
"    <span class=\"h2\">",
"     Laparoscopic transcystic exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic transcystic exploration of the CBD is the preferred initial technique for most patients requiring CBD exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with stones smaller than 10 mm and a small bile duct, laparoscopic transcystic exploration of the CBD is the fastest, safest, and least invasive initial approach to CBD exploration compared with laparoscopic choledochotomy. Morbidity is equivalent to that of a standard laparoscopic cholecystectomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As an example, in an observational series of 113 patients undergoing CBD exploration, operative time (97 versus 75 minutes), and length of hospital stay (6 versus 2 days) were significantly longer for choledochotomy than for transcystic exploration, although stone clearance and morbidity were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Choledochotomy should be reserved for patients with large occluding stones or those in whom the duct cannot be cleared using a transcystic approach. (See",
"    <a class=\"local\" href=\"#H25286341\">",
"     'Laparoscopic choledochotomy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Conditions for successful and safe transcystic laparoscopic CBD exploration include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CBD diameter &lt;6 mm",
"     </li>",
"     <li>",
"      Stone location distal to the cystic",
"      <span class=\"nowrap\">",
"       duct/CBD",
"      </span>",
"      junction",
"     </li>",
"     <li>",
"      Cystic duct diameter &gt;4 mm",
"     </li>",
"     <li>",
"      Fewer than 6 to 8 stones within the CBD",
"     </li>",
"     <li>",
"      Stones smaller than 10 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For laparoscopic transcystic exploration, the gallbladder is left in situ and the dome of the gallbladder is grasped and retracted cephalad to facilitate visualization and manipulation (",
"    <a class=\"graphic graphic_figure graphicRef54280 \" href=\"UTD.htm?13/62/14304\">",
"     figure 2",
"    </a>",
"    ). After intraoperative cholangiography is performed, potential maneuvers and the general sequence that they should be attempted include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Flushing of the CBD",
"      </strong>",
"       Flushing of the distal CBD with warm saline should be the initial maneuver performed for clearance of CBD stones and can be facilitated by intravenous administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      or dilatation of the cystic duct with a 4 to 6 mm balloon. A laparoscopic grasper can be left secured to the dome of the gallbladder in order to facilitate retraction and visualization throughout the procedure. Flushing of the proximal duct is avoided because small stones could be pushed into hepatic ducts, and may not be retrievable.",
"     </li>",
"     <li>",
"      <strong>",
"       Biliary balloon catheter extraction",
"      </strong>",
"       Biliary balloon catheter extraction is useful for cases with a dilated cystic duct [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/13\">",
"       13",
"      </a>",
"      ]. A 3- to 5-F biliary Fogarty catheter is advanced transcystically under fluoroscopic control distally into the duodenum. Duodenal placement can be confirmed by fluoroscopy or by resistance upon withdrawal of the catheter, indicating that the balloon is adjacent to the ampulla of Vater. The balloon should be deflated and withdrawn slightly. The balloon can then be gently inflated and withdrawn carefully until stones and debris exit from the cystic ductotomy for retrieval with forceps. There is a risk of stone displacement into the common hepatic duct with this procedure since the stones are not grasped directly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the duct has been cleared with flushing and balloon catheters, either transcystic choledochoscopy or fluoroscopically-guided wire basket retrieval can be employed to retrieve any remaining stones. The choice between approaches depends on available expertise and equipment as both have been used successfully.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Transcystic choledochoscopy",
"      </strong>",
"      &minus; Transcystic choledochoscopy may require dilatation of the cystic duct to accommodate the scope, although the cystic duct is usually enlarged due to the passage of stones. The choledochoscope is placed through a 5 mm port and manipulated into the cystic duct with atraumatic instruments. The choledochoscope can then be advanced through the CBD and into the duodenum. The choledochoscope should be connected to high-pressure saline for irrigation of the duct and to improve visualization. Adaptors for insertion of wire retrieval baskets are necessary. Additional video monitors, or screen-in-screen technology, are utilized for monitoring.",
"      <br/>",
"      <br/>",
"      If a stone is seen through the choledochoscope, wire basket retrieval can be performed through the working channel of the scope and offers the advantage of direct visualization of stone capture and withdrawal as compared with fluoroscopically-guided wire basket retrieval. Distal CBD stones can be pushed into the duodenum with the choledochoscope. Proximal stones may require treatment with other techniques since choledochoscopic visualization of the proximal biliary tree is technically challenging.",
"      <br/>",
"      <br/>",
"      In an observational series of 113 patients undergoing CBD exploration, operative time (107 versus 75 minutes) was significantly longer for fluoroscopically guided stone retrieval than with choledochoscopy, although stone clearance and morbidity were similar [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Fluoroscopically-guided wire basket retrieval",
"      </strong>",
"       Fluoroscopically-guided wire basket retrieval of stones can be performed if fluoroscopy and specialized equipment are available [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/13\">",
"       13",
"      </a>",
"      ]. The use of spiral wire baskets with flexible leaders will help avoid CBD injury. The basket is placed through the wire for guidance and advanced under fluoroscopic guidance into the lower common duct or duodenum, then opened and pulled back until the stone is captured. Rates of successful stone retrieval with this technique are reported as 95 percent in several case series [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following laparoscopic transcystic exploration, cholangiographic confirmation of duct clearance should be performed with intraoperative cholangiography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59179 \" href=\"UTD.htm?27/63/28657\">",
"     image 5",
"    </a>",
"    ). The cholecystectomy is completed and the cystic duct stump is secured with a clip or a loop ligature. Loop ligatures minimize the possibility of postoperative bile leak for patients with cystic duct dilation, trauma, or inflammation. Placement of a closed suction drain in the hepatic fossa may be considered to identify and control any bile leakage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link&amp;anchor=H12#H12\">",
"     \"Laparoscopic cholecystectomy: Techniques\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25286341\">",
"    <span class=\"h2\">",
"     Laparoscopic choledochotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic choledochotomy (LCD) is more technically challenging than laparoscopic transcystic exploration. LCD may be attempted following failed laparoscopic transcystic exploration or for patients who are not candidates for the transcystic approach. Laparoscopic CBD exploration is preferable to postoperative ERCP for stone removal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/6,16-19\">",
"     6,16-19",
"    </a>",
"    ]. A metaanalysis of surgical versus endoscopic treatment of CBD stones including 1351 patients in 13 randomized trials showed that laparoscopic CBD stone clearance was more successful as well as more efficient than pre- and postoperative ERCP with no significant difference in morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LCD is indicated for patients with [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failed laparoscopic transcystic exploration or preoperative endoscopic stone extraction",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Narrow/tortuous",
"      </span>",
"      cystic duct",
"     </li>",
"     <li>",
"      Dilated CBD (6 to 10 mm)",
"     </li>",
"     <li>",
"      Large stones (&gt;10 mm)",
"     </li>",
"     <li>",
"      Multiple stones",
"     </li>",
"     <li>",
"      Stone location proximal to the cystic",
"      <span class=\"nowrap\">",
"       duct/CBD",
"      </span>",
"      junction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As is the case for laparoscopic transcystic exploration, the gallbladder is left in situ and the dome of the gallbladder can be grasped and retracted cephalad to facilitate visualization and manipulation. A 30 degree laparoscope should be used to assist with visualization of the supraduodenal CBD.",
"   </p>",
"   <p>",
"    The cystic duct should be dissected down to the level of the CBD and the tissue overlying the anterior CBD should be cleared. Care should be taken to avoid excessive dissection because this may endanger the blood supply to the duct and thus impair healing. An approximately 1 cm longitudinal ductotomy is created with laparoscopic scissors; stay sutures will help to facilitate manipulation and maintain a seal when saline infusion is used for choledochoscopy. Various techniques such as saline infusion, fluoroscopically-guided balloon or wire basket retrieval, and choledochoscopy should be utilized for extraction of CBD stones and to ensure that the CBD is no longer obstructed, as described above. (See",
"    <a class=\"local\" href=\"#H25286334\">",
"     'Laparoscopic transcystic exploration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Primary closure of the choledochotomy with interrupted fine monofilament absorbable suture is safer than closure around a T-tube and results in decreased operating time, decreased postoperative and biliary complications, shorter time until return to work, and decreased hospital costs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Absorbable sutures should be used in the bile duct since permanent suture is lithogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/1\">",
"     1",
"    </a>",
"    ]. Residual stones may be extracted with the use of ERCP.",
"   </p>",
"   <p>",
"    In cases where there is concern that additional manipulation may be necessary and ERCP expertise is not available, a T-tube (12- to 16-F) can be placed through the ductotomy and secured in place using fine monofilament absorbable sutures. T-tube drainage has traditionally provided a method for post-operative biliary decompression and postoperative access to the bile duct for cholangiography and possible stone extraction. However, T-tubes can be complicated by bile leak, infection, tube dislodgement, or bile duct obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, the T-tube can act as a foreign body around which bile pigments and bile salts may precipitate, potentially leading to stone recurrence. If a T-tube is placed, cholangiography should always be performed prior to closure in order to confirm duct clearance and to rule out bile leaks.",
"   </p>",
"   <p>",
"    Some surgeons place transcystic biliary drainage catheters as an alternative to T-tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/24\">",
"     24",
"    </a>",
"    ]. These catheters are easier to place than T-tubes and allow for biliary access in the case of retained stones. However, in a study of 63 patients, transcystic biliary drainage catheters resulted in a significantly higher rate of bile leakage as compared to T-tubes (14 versus 3.5 percent respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25286348\">",
"    <span class=\"h2\">",
"     Open CBD exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open CBD exploration remains an important technique and should be part of every gastrointestinal surgeon's armamentarium for treating hepatobiliary diseases. Surgeons performing laparoscopic cholecystectomy should be prepared to convert to open CBD exploration if necessary.",
"   </p>",
"   <p>",
"    Open CBD exploration should be performed in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with CBD stones who are undergoing open cholecystectomy",
"     </li>",
"     <li>",
"      Patients who have failed or suffered complications from laparoscopic CBD exploration",
"     </li>",
"     <li>",
"      Patients with severe inflammation in the triangle of Calot",
"     </li>",
"     <li>",
"      When laparoscopic equipment, experience,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      resources are limited",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The abdomen is most commonly opened through a right upper quadrant subcostal incision; although a midline approach is acceptable as well. The liver should be retracted superiorly, the duodenum retracted inferiorly, and the stomach retracted to the left. A generous Kocher maneuver should be performed, which will allow for manual palpation and manipulation of the distal common bile duct.",
"   </p>",
"   <p>",
"    The proximal cystic duct should be ligated to prevent gallstones from migrating from the gallbladder into the cystic duct and CBD. Dissection is carried out on the anterolateral CBD, stay sutures (fine monofilament, absorbable suture) are placed just above the level of the duodenum and the duct is opened longitudinally. The choledochotomy can then be extended with Potts scissors to a length of approximately 1.5 cm.",
"   </p>",
"   <p>",
"    Stones can initially be extracted using manual manipulation of the CBD. If this is not possible, balloon extraction can be performed with biliary Fogarty catheters, clearing the proximal duct before the distal duct. These catheters are preferred because they are less traumatic than metal forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/25\">",
"     25",
"    </a>",
"    ]. Saline irrigation can facilitate the removal of fragmented debris by flushing. Choledochoscopy with wire basket retrieval can be employed in the unlikely event that balloon extraction is unsuccessful.",
"   </p>",
"   <p>",
"    As is the case for LCD exploration, primary closure of the choledochotomy is a safe alternative to T-tube placement in patients undergoing open CBD exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/20,22,26,27\">",
"     20,22,26,27",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H813533\">",
"    <span class=\"h1\">",
"     PERSISTENT STONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic CBD exploration results in stone clearance in over 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/5,28,29\">",
"     5,28,29",
"    </a>",
"    ]. Options for management of persistent CBD stones after laparoscopic transcystic exploration include conversion to laparoscopic or open choledochotomy and CBD exploration, postoperative ERCP and stone extraction, percutaneous stone removal, or observation (in the case of stones &lt;2 mm) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60642 \" href=\"UTD.htm?8/60/9153\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81598 \" href=\"UTD.htm?32/58/33696\">",
"     image 7",
"    </a>",
"    ). The choice of procedure should be guided by patient-specific considerations (discussed above), training and experience of the surgeon, and available endoscopic expertise.",
"   </p>",
"   <p>",
"    Rarely, severely impacted stones are encountered (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60965 \" href=\"UTD.htm?7/48/7936\">",
"     image 8",
"    </a>",
"    ). Impacted stones are difficult to remove with laparoscopic techniques and remain one of the indications for open CBD exploration. Surgeons who have experience with lithotripsy or duodenotomy with sphincterotomy may be able to complete stone extraction with one of these techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/30\">",
"     30",
"    </a>",
"    ]. However, if experience in sphincterotomy or lithotripsy is not available, the surgeon should place a T-tube and terminate the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/31\">",
"     31",
"    </a>",
"    ]. The patient should be referred postoperatively to a specialized center where endoscopic or percutaneous removal is usually successful with the use of electrohydraulic or laser lithotripsy in conjunction with sphincterotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=see_link\">",
"     \"Laser lithotripsy for the treatment of gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=see_link\">",
"     \"Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25286355\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative care is routine. If closed suction drains were placed at the time of surgery, they are removed within 24 to 48 hours as long as the output is not bilious. Liver function tests (LFTs) should be measured if patients develop complications or if there is a concern for retained stones, but LFTs may take over a week to normalize after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a T-tube has been placed, it is clamped when the patient is discharged and flushed with 10 mL of sterile normal saline one to two times a day. A T-tube cholangiogram and measurement of LFTs should be performed prior to T-tube removal in order to confirm duct clearance and integrity. The T-tube may be safely removed in the office setting after a tract has had time to develop; this generally requires four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H813477\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of open and laparoscopic CBD exploration include bile duct leak (2 to 6 percent), subhepatic abscess (0.7 percent) and retained stones (3 to 6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/29,33,34\">",
"     29,33,34",
"    </a>",
"    ]. Compared with patients who had open surgery, patients who had laparoscopic CBD exploration had significantly lower mortality (0.25 versus 5.5 percent), surgical site infection (1.2 versus 10 percent) and overall morbidity (3.7 versus 22 percent) in the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/35\">",
"     35",
"    </a>",
"    ]. The increased morbidity and mortality in patients who underwent open surgery is likely a reflection of underlying comorbidities or more complicated disease requiring an open approach [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6440/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who present with persistent fever and leukocytosis, persistent pain, bile leakage around the T-tube or drain, jaundice or rigors after CBD exploration should be evaluated for fluid collections or CBD blockage with ultrasound and a computed tomography (CT) scan. The clinical and radiologic evaluation of a bile leak or obstruction is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link&amp;anchor=H14#H14\">",
"     \"Complications of laparoscopic cholecystectomy\", section on 'Radiologic workup'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H465889\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common bile duct (CBD) stones are identified in 10 to 15 percent of patients undergoing surgery for symptomatic cholelithiasis. Complications of CBD stones include acute suppurative cholangitis, obstructive jaundice, hepatic abscess, and acute pancreatitis. (See",
"      <a class=\"local\" href=\"#H25286312\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with symptomatic cholelithiasis should be evaluated for possible CBD stones. Clinical findings suggestive of CBD stones include right upper quadrant pain with radiation to the back, jaundice, cholangitis, and pancreatitis. The preoperative evaluation includes liver function tests and imaging (typically ultrasonography). Although some surgeons perform routine intraoperative cholangiography prior to CBD exploration, we selectively perform intraoperative cholangiography based upon findings of elevated liver function tests, a dilated common bile duct (&gt;6 mm), or a history of pancreatitis. Patients who present with jaundice may be best evaluated preoperatively using ERCP. (See",
"      <a class=\"local\" href=\"#H813094\">",
"       'Intraoperative cholangiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exploration of the CBD should be performed in all patients with CBD stones who have either failed, or are not candidates for, endoscopic therapy and who do not have medical conditions that prohibit surgical intervention. (See",
"      <a class=\"local\" href=\"#H11839322\">",
"       'Indications for CBD exploration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic CBD exploration, open CBD exploration, and postoperative ERCP with stone removal are all options for the treatment of CBD stones identified by intraoperative cholangiography. Laparoscopic CBD exploration may be performed by a transcystic approach or by choledochotomy. The choice of procedure should be guided by patient-specific considerations, training and experience of the surgeon, and available endoscopic expertise. (See",
"      <a class=\"local\" href=\"#H25286327\">",
"       'Surgical approaches for CBD exploration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing laparoscopic surgery, we recommend laparoscopic transcystic exploration of the CBD as the initial surgical approach for patients with stones smaller than 10 mm and a small bile duct (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ) . Choledochotomy should be reserved for patients in whom the duct cannot be cleared using a transcystic approach. (See",
"      <a class=\"local\" href=\"#H25286334\">",
"       'Laparoscopic transcystic exploration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgeons performing laparoscopic cholecystectomy should be prepared to convert to open CBD exploration if necessary. (See",
"      <a class=\"local\" href=\"#H25286348\">",
"       'Open CBD exploration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/1\">",
"      Verbesey JE, Birkett DH. Common bile duct exploration for choledocholithiasis. Surg Clin North Am 2008; 88:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/2\">",
"      Barkun AN, Barkun JS, Fried GM, et al. Useful predictors of bile duct stones in patients undergoing laparoscopic cholecystectomy. McGill Gallstone Treatment Group. Ann Surg 1994; 220:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/3\">",
"      NIH state-of-the-science statement on endoscopic retrograde cholangiopancreatography (ERCP) for diagnosis and therapy. NIH Consens State Sci Statements 2002; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/4\">",
"      Hunter JG, Soper NJ. Laparoscopic management of bile duct stones. Surg Clin North Am 1992; 72:1077.",
"     </a>",
"    </li>",
"    <li>",
"     Mellinger, JD, MacFayden, BD. Laparoscopic common bile duct exploration. In: Current Surgical Therapy, 9th edition, Cameron, JL (Eds), Mosby, Philadelphia 2008. p.1276.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/6\">",
"      Martin DJ, Vernon DR, Toouli J. Surgical versus endoscopic treatment of bile duct stones. Cochrane Database Syst Rev 2006; :CD003327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/7\">",
"      Shojaiefard A, Esmaeilzadeh M, Ghafouri A, Mehrabi A. Various techniques for the surgical treatment of common bile duct stones: a meta review. Gastroenterol Res Pract 2009; 2009:840208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/8\">",
"      Hanif F, Ahmed Z, Samie MA, Nassar AH. Laparoscopic transcystic bile duct exploration: the treatment of first choice for common bile duct stones. Surg Endosc 2010; 24:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/9\">",
"      Rojas-Ortega S, Arizpe-Bravo D, Mar&iacute;n L&oacute;pez ER, et al. Transcystic common bile duct exploration in the management of patients with choledocholithiasis. J Gastrointest Surg 2003; 7:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/10\">",
"      Topal B, Aerts R, Penninckx F. Laparoscopic common bile duct stone clearance with flexible choledochoscopy. Surg Endosc 2007; 21:2317.",
"     </a>",
"    </li>",
"    <li>",
"     Matthews, BD, Strasberg, SM. Management of common duct stones. In: Current Surgical Therapy, 9th edition, Cameron, JL (Eds), Mosby, Philadelphia 2008. p.412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/12\">",
"      Memon MA, Hassaballa H, Memon MI. Laparoscopic common bile duct exploration: the past, the present, and the future. Am J Surg 2000; 179:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/13\">",
"      Lyass S, Phillips EH. Laparoscopic transcystic duct common bile duct exploration. Surg Endosc 2006; 20 Suppl 2:S441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/14\">",
"      Rhodes M, Nathanson L, O'Rourke N, Fielding G. Laparoscopic exploration of the common bile duct: lessons learned from 129 consecutive cases. Br J Surg 1995; 82:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/15\">",
"      Paganini AM, Guerrieri M, Sarnari J, et al. Thirteen years' experience with laparoscopic transcystic common bile duct exploration for stones. Effectiveness and long-term results. Surg Endosc 2007; 21:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/16\">",
"      Nathanson LK, O'Rourke NA, Martin IJ, et al. Postoperative ERCP versus laparoscopic choledochotomy for clearance of selected bile duct calculi: a randomized trial. Ann Surg 2005; 242:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/17\">",
"      Rhodes M, Sussman L, Cohen L, Lewis MP. Randomised trial of laparoscopic exploration of common bile duct versus postoperative endoscopic retrograde cholangiography for common bile duct stones. Lancet 1998; 351:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/18\">",
"      Cuschieri A, Lezoche E, Morino M, et al. E.A.E.S. multicenter prospective randomized trial comparing two-stage vs single-stage management of patients with gallstone disease and ductal calculi. Surg Endosc 1999; 13:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/19\">",
"      Williams EJ, Green J, Beckingham I, et al. Guidelines on the management of common bile duct stones (CBDS). Gut 2008; 57:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/20\">",
"      Gurusamy KS, Samraj K. Primary closure versus T-tube drainage after laparoscopic common bile duct stone exploration. Cochrane Database Syst Rev 2007; :CD005641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/21\">",
"      Jameel M, Darmas B, Baker AL. Trend towards primary closure following laparoscopic exploration of the common bile duct. Ann R Coll Surg Engl 2008; 90:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/22\">",
"      Zhu QD, Tao CL, Zhou MT, et al. Primary closure versus T-tube drainage after common bile duct exploration for choledocholithiasis. Langenbecks Arch Surg 2011; 396:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/23\">",
"      Leida Z, Ping B, Shuguang W, Yu H. A randomized comparison of primary closure and T-tube drainage of the common bile duct after laparoscopic choledochotomy. Surg Endosc 2008; 22:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/24\">",
"      Tang CN, Tai CK, Ha JP, et al. Antegrade biliary stenting versus T-tube drainage after laparoscopic choledochotomy--a comparative cohort study. Hepatogastroenterology 2006; 53:330.",
"     </a>",
"    </li>",
"    <li>",
"     Cushieri, A. Common bile duct exploration. In: Maingot's abdominal operations, Zinner, MJ, Schwartz, SI, Ellis, H (Eds), Appleton and Lange, Stamford 1997. p.1875.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/26\">",
"      Ahmed I, Pradhan C, Beckingham IJ, et al. Is a T-tube necessary after common bile duct exploration? World J Surg 2008; 32:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/27\">",
"      Yamazaki M, Yasuda H, Tsukamoto S, et al. Primary closure of the common bile duct in open laparotomy for common bile duct stones. J Hepatobiliary Pancreat Surg 2006; 13:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/28\">",
"      Tinoco R, Tinoco A, El-Kadre L, et al. Laparoscopic common bile duct exploration. Ann Surg 2008; 247:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/29\">",
"      Petelin JB. Laparoscopic common bile duct exploration. Surg Endosc 2003; 17:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/30\">",
"      Lo Menzo E, Schnall R, Von Rueden D. Lithotripsy in the laparoscopic era. JSLS 2005; 9:358.",
"     </a>",
"    </li>",
"    <li>",
"     Matthews, BD, Strasberg, SM. Management of common bile duct stones. In: Current Surgical Therapy, Ninth Edition, Cameron, JL (Eds), Mosby Elsevier, 2008. p.412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/32\">",
"      Saber AA, Laraja RD, Nalbandian HI, et al. Changes in liver function tests after laparoscopic cholecystectomy: not so rare, not always ominous. Am Surg 2000; 66:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/33\">",
"      Paganini AM, Feliciotti F, Guerrieri M, et al. Laparoscopic common bile duct exploration. J Laparoendosc Adv Surg Tech A 2001; 11:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/34\">",
"      Horwood J, Akbar F, Davis K, Morgan R. Prospective evaluation of a selective approach to cholangiography for suspected common bile duct stones. Ann R Coll Surg Engl 2010; 92:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/35\">",
"      Ingraham AM, Cohen ME, Ko CY, Hall BL. A current profile and assessment of north american cholecystectomy: results from the american college of surgeons national surgical quality improvement program. J Am Coll Surg 2010; 211:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6440/abstract/36\">",
"      Wolf AS, Nijsse BA, Sokal SM, et al. Surgical outcomes of open cholecystectomy in the laparoscopic era. Am J Surg 2009; 197:781.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15093 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6440=[""].join("\n");
var outline_f6_18_6440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H465889\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25286312\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25286320\">",
"      IDENTIFICATION OF CBD STONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11839322\">",
"      INDICATIONS FOR CBD EXPLORATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11839696\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1382386448\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H813094\">",
"      INTRAOPERATIVE CHOLANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25286327\">",
"      SURGICAL APPROACHES FOR CBD EXPLORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25286334\">",
"      Laparoscopic transcystic exploration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25286341\">",
"      Laparoscopic choledochotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25286348\">",
"      Open CBD exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H813533\">",
"      PERSISTENT STONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25286355\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H813477\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H465889\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15093|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/3/26686\" title=\"algorithm 1\">",
"      Patient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15093|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/40/34447\" title=\"diagnostic image 1\">",
"      Common bile duct stone on MRCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/14/44256\" title=\"diagnostic image 2\">",
"      MR cholangiogram showing common bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/33/18963\" title=\"diagnostic image 3\">",
"      Endoscopic ultrasound image of a gallstone in the gallbladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/29/10707\" title=\"diagnostic image 4\">",
"      Common bile duct stone on cholangiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/63/28657\" title=\"diagnostic image 5\">",
"      Normal intraoperative cholangiogram after cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/60/9153\" title=\"diagnostic image 6\">",
"      Balloon extraction of common bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/58/33696\" title=\"diagnostic image 7\">",
"      ERCP showing common bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/48/7936\" title=\"diagnostic image 8\">",
"      Impacted common bile duct stone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15093|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/3/25649\" title=\"figure 1\">",
"      Critical view of safety in laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/62/14304\" title=\"figure 2\">",
"      Laparoscopic transcystic bile duct exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/54/35693\" title=\"table 2\">",
"      Perioperative VTE prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/28/40395\" title=\"table 3\">",
"      JCAHO protocol for surgical timeout",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12854?source=related_link\">",
"      Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16856?source=related_link\">",
"      Laser lithotripsy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=related_link\">",
"      Percutaneous transhepatic cholangiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_18_6441="Perimesencephalic nonaneurysmal subarachnoid hemorrhage";
var content_f6_18_6441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perimesencephalic nonaneurysmal subarachnoid hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6441/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6441/contributors\">",
"     Farhan Siddiq, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6441/contributors\">",
"     Amir S Khan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6441/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/18/6441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/18/6441/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/18/6441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid hemorrhage (SAH) refers to bleeding within the subarachnoid space, which lies between the arachnoid and pia mater and is normally filled with cerebrospinal fluid. Most cases of subarachnoid hemorrhage are caused by rupture of an intracranial aneurysm, but approximately 15 to 20 percent of patients do not have an established vascular lesion on initial four-vessel cerebral angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The causes of nonaneurysmal SAH (NASAH) are potentially diverse, and often the mechanism of bleeding in these cases is not identified.",
"   </p>",
"   <p>",
"    In 1985, a subtype of NASAH, so-called perimesencephalic nonaneurysmal SAH was identified in a case series of 13 patients who had a characteristic pattern of localized blood on computed tomography (CT), normal cerebral angiography, and a benign course that distinguished these patients from both aneurysmal SAH and other patients with nonaneurysmal SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/3\">",
"     3",
"    </a>",
"    ]. This observation has subsequently been confirmed by other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/2,4-7\">",
"     2,4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CT finding that defines perimesencephalic NASAH (PM-NASAH) is blood isolated to the perimesencephalic cisterns anterior to the brainstem; there may also be extension into the ambient cisterns or basal parts of the sylvian fissures, but not into the lateral sylvian fissure, anterior interhemispheric fissure, or lateral ventricles (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76973 \" href=\"UTD.htm?40/12/41158\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74410 \" href=\"UTD.htm?38/9/39063\">",
"     figure 1",
"    </a>",
"    ). This CT pattern of hemorrhage is not specific to PM-NASAH; a subset of cases of perimesencephalic SAH are caused by aneurysm rupture. It is important, however, to recognize this pattern of bleeding because invasive diagnostic testing can be limited in these patients and morbidity thereby reduced.",
"   </p>",
"   <p>",
"    This topic reviews perimesencephalic SAH. Aneurysmal SAH and other causes of NASAH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported proportion of cases of NASAH that are PM-NASAH varies between 21 to 68 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,2,6,8-11\">",
"     1,2,6,8-11",
"    </a>",
"    ]. In a biracial, population-based, epidemiologic study, the annual rate of PM-NASAH was estimated to be 0.5 per 100,000 persons over 18 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean age of occurrence of PM-NASAH in several series was between 50 and 55 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ]. However, the age in reported cases ranges from 3 to 72 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,7,14-16\">",
"     1,7,14-16",
"    </a>",
"    ]. In contrast to aneurysmal SAH, there is no clear female predisposition for PM-NASAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case-control studies suggest that hypertension and cigarette smoking are risk factors for PM-NASAH, but these appear to be somewhat less prevalent among patients with PM-NASAH compared with patients with aneurysmal SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/8,17,18\">",
"     8,17,18",
"    </a>",
"    ]. PM-NASAH is not known to have a familial predisposition; however two cases in first-degree relatives have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ruptured saccular aneurysm is the cause of perimesencephalic SAH in 2 to 9 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,3,5,20-23\">",
"     1,3,5,20-23",
"    </a>",
"    ]. The aneurysm in these cases arises from the posterior circulation: the basilar tip, vertebrobasilar junction, or the posterior inferior cerebellar, superior cerebellar, posterior cerebral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/5,15,24,25\">",
"     5,15,24,25",
"    </a>",
"    ]. Posterior circulation aneurysms are less common than those arising from the anterior circulation. When posterior circulation aneurysms rupture, this pattern of SAH results less than 17 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the majority of cases of PM-NASAH, the etiology is not defined, even after extensive evaluation. Theories regarding its origin in some or all cases include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rupture of a perforating artery",
"      </strong>",
"      &mdash; The perimesencephalic location of the blood clots is consistent with bleeding from a perforating artery arising from the posterior circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/27\">",
"       27",
"      </a>",
"      ]. In one case, this pathogenesis has been substantiated pathologically [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/28\">",
"       28",
"      </a>",
"      ]. In addition, hypertension, a known risk factor for perforating artery disease, is also a risk factor for PM-NASAH (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      In one case series of 25 patients with PM-NASAH, an acute lacunar infarction (usually attributed to occlusive disease of the perforating arteries) was found in four patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/29\">",
"       29",
"      </a>",
"      ]. However, the acute lacunar infarctions in this and other reports have been in the distribution of the anterior circulation, and their relationship to the PM-NASAH is not clear [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,30\">",
"       1,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Venous origin",
"      </strong>",
"      &mdash; A venous source for PM-NASAH is suggested by the limited extension of blood and low rate of subsequent rebleeding, both suggesting a low pressure bleeding source. PM-NASAH often occurs in the setting of physical exertion, which in this paradigm sequentially produces increased intrathoracic pressure, impaired internal jugular venous return, elevated intracranial venous pressure, and leakage of venous blood from susceptible blood vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/31\">",
"       31",
"      </a>",
"      ]. Physical exertion is also believed to increase rupture from arterial pathology, including saccular aneurysms.",
"      <br/>",
"      <br/>",
"      In two case series, a higher incidence of primitive venous drainage on conventional or computed tomography (CT) venography was found in patients with PM-NASAH when compared with aneurysmal SAH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In these patients, the basal vein of Rosenthal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the perimesencephalic veins drain directly into the dural sinuses rather than the vein of Galen, potentially making them more susceptible to venous congestion. Two additional reported cases of PM-NASAH have documented a vein of Galen stenosis on conventional and CT venography respectively, providing evidence of a venous origin of bleeding in these cases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/34\">",
"       34",
"      </a>",
"      ]. Another case report documented PM-NASAH along with venous infarction and cerebral venous thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Basilar artery wall hematoma",
"      </strong>",
"      &mdash; In some cases of PM-NASAH, an abnormal contour of the basilar artery has been observed, either a small bulge or luminal narrowing [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/26,36\">",
"       26,36",
"      </a>",
"      ]. This was interpreted as possible vasospasm in some reports, but others have speculated that an intramural hematoma could account for the abnormal blood vessel appearance and also be the source of bleeding. It is postulated that rupture of the vasa vasorum is the source of the relatively limited bleeding that occurs in PM-NASAH. This is in contrast to an arterial dissection that results from an intimal tear and produces massive SAH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=see_link&amp;anchor=H8#H8\">",
"       \"Nonaneurysmal subarachnoid hemorrhage\", section on 'Intracranial arterial dissection'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The role of a putative basilar artery wall hematoma in PM-NASAH remains unproven. In one case series, systematic examination of basilar artery contours in 27 patients with PM-NASAH found no variations that suggested this origin of bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/9\">",
"       9",
"      </a>",
"      ]. This hypothesis awaits further study with high-resolution neuroimaging studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other potential causes of PM-NASAH include rupture of a cryptic vascular malformation, high cervical spinal dural arteriovenous fistula, cavernous angioma, or capillary telangiectasia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Some patients with PM-NASAH may have an occult aneurysm; however, the low incidence of rebleeding in these patients suggests that this is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of PM-NASAH are generally less severe than those of aneurysmal SAH, but the presentation is otherwise similar, with sudden onset of headache, meningismus, photophobia, and nausea being the most common symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Individual patients with PM-NASAH and other forms of SAH cannot be distinguished based upon their clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Group comparisons of patients with PM-NASAH and aneurysmal SAH find differences in the prevalence of certain clinical features and measures of disease severity. Some examples of these differences, as well as similarities, are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On initial evaluation in the hospital, over 90 percent of patients with PM-NASAH are categorized in lower Hunt and Hess grades, a measure of the clinical severity of the SAH (",
"      <a class=\"graphic graphic_table graphicRef69179 \" href=\"UTD.htm?8/57/9115\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,6,7,13,14,40\">",
"       1,6,7,13,14,40",
"      </a>",
"      ]. In contrast, less than 50 percent of patients with aneurysmal SAH present with these relatively benign clinical features [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/6,14\">",
"       6,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frank loss of consciousness at the onset of SAH is reported to be less common in patients with PM-NASAH than in patients with aneurysmal rupture. However, this clinical feature is variably reported, and in one series, occurred in one-third of patients with PM-NASAH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/41\">",
"       41",
"      </a>",
"      ]. Another case series reported that one-third of patients with PM-NASAH suffered an episode of amnesia at the ictus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/42\">",
"       42",
"      </a>",
"      ]. The speculative cause was transient hydrocephalus, with enlarged temporal horns causing temporary hypoperfusion of the hippocampus.",
"     </li>",
"     <li>",
"      The onset of headache in PM-NASAH appeared to be somewhat less abrupt (a few minutes rather than a few seconds) than in patients with aneurysmal SAH in one case series [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/3\">",
"       3",
"      </a>",
"      ]. However, the relatively small differences in the time course were not statistically significant.",
"     </li>",
"     <li>",
"      Sentinel headache, a prodromal feature of up to 40 percent of patients with aneurysmal SAH, is not reported in PM-NASAH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clinical setting of physical exertion appears to be as common in PM-NASAH as in aneurysmal SAH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/3,7,26,31\">",
"       3,7,26,31",
"      </a>",
"      ]. The onset of both PM-NASAH and aneurysmal SAH are more common during daytime and evening hours compared with nighttime [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid hemorrhage (SAH) should be considered in any patient complaining of severe headache of sudden onset. Emergent computed tomography (CT) of the head should immediately follow consideration of the diagnosis. If the suspicion is high and the CT scan fails to show blood in subarachnoid space, a lumbar puncture must be obtained. CT scan can detect SAH, but cerebral angiography is required to exclude aneurysmal bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H26#H26\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of blood on CT scan identifies a patient with perimesencephalic SAH. Blood is isolated to the perimesencephalic cisterns anterior to the brainstem; there may be extension into the ambient cisterns or basal parts of the sylvian fissures, but not into the lateral sylvian fissure, anterior interhemispheric fissure, chiasmatic cistern, or lateral ventricles (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76973 \" href=\"UTD.htm?40/12/41158\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74410 \" href=\"UTD.htm?38/9/39063\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,5,44,45\">",
"     1,5,44,45",
"    </a>",
"    ]. In some patients, the visualized blood is limited to the quadrigeminal or pretruncal cisterns [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. There is high inter-observer agreement among radiologists in the identification of perimesencephalic SAH (kappa 0.87) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of the CT scan is critical. A diagnosis of perimesencephalic SAH should not be considered reliable on a CT performed more than 48 to 72 hours after the clinical ictus, as washout and resorption of blood may have taken place and obscured the initial extent of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,7,47\">",
"     1,7,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cerebral angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of finding an aneurysm on angiogram in a patient with a perimesencephalic SAH has varied from 2 to 9 percent in different reports. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology and pathogenesis'",
"    </a>",
"    above.) Because of the very high and immediate morbidity and mortality associated with aneurysmal bleeding, every patient with perimesencephalic SAH must undergo angiographic evaluation. The commonly used angiographic techniques include CT angiography (CTA), magnetic resonance angiography (MRA), and conventional digital subtraction angiography (DSA). The best modality for evaluation of cerebral vasculature in perimesencephalic SAH is controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Choice of first test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the available tests, DSA is believed to have the highest resolution for the detection of intracranial aneurysms and remains the gold standard test. While invasive with an associated risk of serious complications, DSA has a relatively low morbidity in this setting. In one meta-analysis, the combined risk of permanent and transient neurologic complications following DSA was significantly lower in patients with SAH compared with those with a TIA or stroke (1.8 versus 3.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of the two noninvasive angiographic techniques, CTA and MRA, CTA has been best studied in the setting of acute SAH. A 2003 meta-analysis of 21 studies involving 1251 patients estimated the overall sensitivity and specificity of CTA for aneurysm detection to be 93 and 88 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/49\">",
"     49",
"    </a>",
"    ]. However, there is likely to be appreciable inter-institutional variability. A subsequently reported series of 336 patients found a lower per-aneurysm sensitivity and specificity of 83 and 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/50\">",
"     50",
"    </a>",
"    ]. Aneurysms smaller than 3 mm were particularly likely to be missed by CTA. As technology improves, the sensitivity and specificity of noninvasive imaging is also likely to improve. [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/51\">",
"     51",
"    </a>",
"    ]. A 2011 meta-analysis of CTA diagnosis of intracranial aneurysms found that, compared with single-detector CTA, use of multidetector CTA was associated with an overall improved sensitivity and specificity for aneurysm detection (both &gt;97 percent) as well as improved detection of smaller aneurysms &le;4 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/52\">",
"     52",
"    </a>",
"    ]. Another systematic review and meta-analysis restricted to patients with SAH had similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific information regarding the performance of CTA for posterior circulation aneurysms and perimesencephalic SAH is more limited. In one study of 40 patients with SAH localized to the posterior fossa, CTA detected aneurysms in 16 patients. In all 40 patients, the presence and absence of aneurysm as determined by CTA was confirmed by DSA or autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/21\">",
"     21",
"    </a>",
"    ]. However, none of the 15 patients with PM-SAH in this series was found to have an intracranial aneurysm. Similarly, DSA confirmed the negative findings on CTA in another case series of 30 patients with PM-SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decision analysis reported that CTA alone had higher utilities in the setting of perimesencephalic SAH compared with other diagnostic strategies including no investigation, DSA alone, and CTA plus DSA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/20\">",
"     20",
"    </a>",
"    ]. However, certain assumptions in the analysis, including a low prevalence of aneurysm (4 percent), a high complication rate of angiography (2.7 morbidity and mortality), and a 97 percent sensitivity and specificity of CTA, favored this outcome and can be disputed.",
"   </p>",
"   <p>",
"    CTA technology is continuously evolving and varies, along with expertise of interpretation, at different institutions. As a result, we recommend DSA over CTA as a first test for most patients with PM-SAH. Centers with a high volume of cases of SAH and demonstrated, documented experience with CTA for this purpose may choose CTA over DSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Repeated testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When DSA is repeated after an initial first study in patients with SAH, an aneurysm may be revealed in 2 to 24 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,6,10,55\">",
"     1,6,10,55",
"    </a>",
"    ]. Reasons for an initial false negative angiogram include technical or reading errors, small aneurysm size, and obscuration of the aneurysm because of vasospasm, hematoma, or thrombosis within the aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/6,25\">",
"     6,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A false negative angiogram in the setting of perimesencephalic SAH is a rare but reported event [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/6,10,13,25,55-57\">",
"     6,10,13,25,55-57",
"    </a>",
"    ]. Many clinicians feel that repeat angiography is not necessary for patients with perimesencephalic SAH unless the initial angiogram is felt to be technically compromised because of vasospasm or other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1-4,58\">",
"     1-4,58",
"    </a>",
"    ]. Others disagree and advocate repeating DSA in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/47\">",
"     47",
"    </a>",
"    ]. A conservative, middle-road approach advocates follow-up imaging with noninvasive CTA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/6,57\">",
"     6,57",
"    </a>",
"    ]. It is our practice to repeat CTA seven days after the onset of PM-SAH. Rebleeding suggests the presence of an occult aneurysm and is an indication for repeat DSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) may demonstrate angiographically occult vascular lesions that can cause SAH. Such lesions include vascular malformations in the brain or spinal cord, tumors, including pituitary adenoma, and arterial wall hematoma suggesting arterial dissection. These rarely, if ever, underlie PM-NASAH. In one series of 18 patients with PM-NASAH, MRI revealed a potential causative vascular lesion, a pontine capillary telangiectasia, in just one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/38,59\">",
"     38,59",
"    </a>",
"    ]. In another series of 25 patients with PM-SAH, MRI demonstrated acute lacunar-type infarctions in four individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/29\">",
"     29",
"    </a>",
"    ]. Arguably, these findings did not contribute to the care of the patient. Many clinicians feel that MRI is not cost effective in the evaluation of patients with PM-SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/4,7,55\">",
"     4,7,55",
"    </a>",
"    ]. However, we recommend MRI and MRA in all patients with PM-NASAH; it is noninvasive and safe and may rarely reveal an occult aneurysm as well as other less common causes of PM-NASAH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SAH should undergo basic laboratory testing including complete blood count, serum chemistries, and coagulation studies. A baseline electrocardiogram should also be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical case series report that patients with nonaneurysmal PM-SAH have a lower incidence and severity of complications compared with patients with aneurysmal SAH and patients with nonaneurysmal, nonperimesencephalic SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/2,11,14,60,61\">",
"     2,11,14,60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rebleeding is rare among patients with PM-SAH after an initial negative angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/2,4,6,7,14,60,62\">",
"       2,4,6,7,14,60,62",
"      </a>",
"      ]. In those patients in whom rebleeding occurs, an occult cerebral aneurysm seems likely because the pattern of recurrent hemorrhage is often not perimesencephalic [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/6,41\">",
"       6,41",
"      </a>",
"      ]. Rebleeding represents an indication for repeat DSA.",
"     </li>",
"     <li>",
"      Vasospasm with cerebral ischemia is the leading cause of death and disability after aneurysm rupture, occurring in 20 to 30 percent of patients with aneurysmal SAH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/63\">",
"       63",
"      </a>",
"      ]. In PM-NASAH, vasospasm appears to be somewhat less common and to be associated with somewhat milder clinical symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/4,6,7,14,41,47,60\">",
"       4,6,7,14,41,47,60",
"      </a>",
"      ]. However, there are reported cases of symptomatic, diffuse, and severe vasospasm affecting the anterior and posterior circulations in patients with PM-NASAH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/2,64-66\">",
"       2,64-66",
"      </a>",
"      ]. Symptomatic vasospasm has been precipitated by DSA in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,7,60\">",
"       1,7,60",
"      </a>",
"      ]. The lower incidence of vasospasm in PM-NASAH may be due to the lower volume or concentration of blood in these patients, although this specific association has not been demonstrated.",
"      <br/>",
"      <br/>",
"      Transcranial Doppler (TCD) sonography is useful for detecting and monitoring vasospasm in spontaneous SAH [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. The pathogenesis of vasospasm in SAH is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H15#H15\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Vasospasm'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hydrocephalus can be an early or delayed complication of SAH. In PM-NASAH, acute hydrocephalus occurs in 3 to 27 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/2,4,6,7,13,14,41,60,69\">",
"       2,4,6,7,13,14,41,60,69",
"      </a>",
"      ], a rate similar to aneurysmal SAH. One case series found that among their patients with PM-NASAH, filling of all perimesencephalic cisterns was a prerequisite for developing hydrocephalus [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/69\">",
"       69",
"      </a>",
"      ]. In more than half of the cases, hydrocephalus resolved spontaneously without intervention (ventriculostomy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shunting), perhaps because of rapid washout of blood limited to the cisterns.",
"     </li>",
"     <li>",
"      Acute seizures have been described in PM-NASAH, but this is uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/41\">",
"       41",
"      </a>",
"      ]. PM-NASAH does not appear to be associated with the later development of epilepsy.",
"     </li>",
"     <li>",
"      Hyponatremia following SAH is due to increased secretion of antidiuretic hormone. In one series, 10 of 35 patients with PM-NASAH developed hyponatremia, only five of whom had sodium levels less than 130",
"      <span class=\"nowrap\">",
"       mmol/liter",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=see_link\">",
"       \"Cerebral salt-wasting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac abnormalities and electrocardiographic (ECG) changes are commonly seen after SAH, ranging in severity from transient ST segment depression to life-threatening cardiac arrhythmias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H24#H24\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Cardiac abnormalities'",
"      </a>",
"      .) In one case series of PM-NASAH, baseline ECG changes were found in 22 percent on admission and transient ECG changes occurred in most [",
"      <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1,60\">",
"       1,60",
"      </a>",
"      ]. No clinically significant cardiac complications have been reported in the setting of PM-NASAH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PM-SAH should be treated as though there is an underlying aneurysm until this has been satisfactorily excluded. Patients are admitted to an intensive care setting for constant hemodynamic and cardiac monitoring, given stool softeners, kept at bedrest, and given analgesia to diminish hemodynamic fluctuations and lower the risk of rebleeding. Pneumatic compression stockings to limit risk of deep vein thrombosis should be utilized while patients are immobile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After exclusion of cerebral aneurysm, patients with PM-NASAH should continue to receive symptomatic care with analgesics as needed, cardiac monitoring, serum chemistry monitoring, and monitoring of neurologic status [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/1\">",
"     1",
"    </a>",
"    ]. Blood pressure should be monitored and controlled, but strict bed rest is not required. The risk of epileptic seizures is low and prophylactic antiepileptic drugs are not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The calcium channel blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    has been shown to improve outcomes in patients with aneurysmal SAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Nimodipine'",
"    </a>",
"    .) The mechanism of its action is uncertain, but may involve some type of neuroprotection against vasospasm-induced cerebral ischemia. It is less certain that patients with other mechanisms of SAH also benefit from nimodipine; meta-analyses of trial results in traumatic SAH, for example, have provided conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no data as to whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    provides any benefit for patients with PM-NASAH, who as a group incur little if any serious neurologic mortality and morbidity. At the same time, nimodipine is unlikely to be associated with significant adverse effects in this group. We suggest that patients with PM-SAH be treated and monitored as if there is a cerebral aneurysm with nimodipine and transcranial Doppler monitoring until follow-up imaging has excluded an aneurysm. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Repeated testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While complications following PM-NASAH, are less likely than after aneurysmal SAH, they should be managed similarly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Management of complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with aneurysmal SAH, patients with PM-NASAH have a good outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/2,6,60\">",
"     2,6,60",
"    </a>",
"    ]. Long-term follow-up studies reveal that rebleeding is exceptional and life expectancy is not altered [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/12,14,62,73\">",
"     12,14,62,73",
"    </a>",
"    ]. With rare exception, patients do not have significant neurologic deficits after PM-NASAH. Some uncontrolled studies suggest that many patients report residual headaches, depression, minor cognitive deficits, and fatigue several years after the PM-NASAH, in some cases affecting employment status [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/4,12,73,74\">",
"     4,12,73,74",
"    </a>",
"    ]. Persistent anosmia is an infrequent (5 percent) complication of PM-NASAH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/75\">",
"     75",
"    </a>",
"    ]. However, one study found that quality of life after PM-NASAH two years after hemorrhage was not significantly different from controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/18/6441/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perimesencephalic nonaneurysmal subarachnoid hemorrhage (PM-NASAH) refers to a subset of SAH patients with characteristic pattern of localized blood on computed tomography (CT), normal cerebral angiography, and a benign course.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 4 and 9 percent of perimesencephalic SAH are caused by rupture of an aneurysm arising from the posterior circulation. Most of the remainder of PM-NASAH do not have an identified etiology. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of PM-NASAH overlaps with aneurysmal SAH with abrupt onset of headache, meningismus, photophobia, and nausea. As a group, patients with PM-NASAH have milder clinical features than those with aneurysmal SAH. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of perimesencephalic SAH is made by CT of the brain, which should always be performed emergently in a patient with an abrupt onset of headache. The CT findings that define perimesencephalic SAH include blood isolated to the perimesencephalic cisterns anterior to the brainstem; there may be extension into the ambient cisterns or basal parts of the sylvian fissures, but not into the lateral sylvian fissure, anterior interhemispheric fissure, or lateral ventricles. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An intracranial aneurysm should be excluded in all patients with perimesencephalic SAH. We suggest using digital subtraction cerebral angiography (DSA). In centers that have a large experience with reliable CT angiography (CTA), this may replace DSA. Repeat angiography should be done in patients in whom concerns for underlying aneurysm remain because of underlying vasospasm or the technical quality of the initial study. Patients who have recurrent bleeding should also have a repeat study. We also recommend a follow-up CTA in all patients one week after the onset of PM-SAH. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cerebral angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with perimesencephalic SAH who are found to have a cerebral aneurysm should be managed as are other patients with aneurysmal SAH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"       \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with perimesencephalic nonaneurysmal SAH (PM-NASAH) have a lower incidence of complications than patients with aneurysmal SAH. Patients should be clinically monitored for the development of clinical vasospasm, hydrocephalus, hyponatremia, and cardiac complications. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aside from monitoring, specific treatments are not required for patients with PM-NASAH. However, until a cerebral aneurysm has been excluded on follow-up imaging, we suggest using prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=see_link\">",
"       nimodipine",
"      </a>",
"      to ameliorate complications of potential vasospasm (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term prognosis for patients with PM-NASAH is in general excellent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Long-term prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31890620\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. David Brock, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/1\">",
"      Schwartz TH, Solomon RA. Perimesencephalic nonaneurysmal subarachnoid hemorrhage: review of the literature. Neurosurgery 1996; 39:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/2\">",
"      Rinkel GJ, Wijdicks EF, Hasan D, et al. Outcome in patients with subarachnoid haemorrhage and negative angiography according to pattern of haemorrhage on computed tomography. Lancet 1991; 338:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/3\">",
"      van Gijn J, van Dongen KJ, Vermeulen M, Hijdra A. Perimesencephalic hemorrhage: a nonaneurysmal and benign form of subarachnoid hemorrhage. Neurology 1985; 35:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/4\">",
"      Canh&atilde;o P, Ferro JM, Pinto AN, et al. Perimesencephalic and nonperimesencephalic subarachnoid haemorrhages with negative angiograms. Acta Neurochir (Wien) 1995; 132:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/5\">",
"      Rinkel GJ, Wijdicks EF, Vermeulen M, et al. Nonaneurysmal perimesencephalic subarachnoid hemorrhage: CT and MR patterns that differ from aneurysmal rupture. AJNR Am J Neuroradiol 1991; 12:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/6\">",
"      Jung JY, Kim YB, Lee JW, et al. Spontaneous subarachnoid haemorrhage with negative initial angiography: a review of 143 cases. J Clin Neurosci 2006; 13:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/7\">",
"      Wijdicks EF, Schievink WI, Miller GM. Pretruncal nonaneurysmal subarachnoid hemorrhage. Mayo Clin Proc 1998; 73:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/8\">",
"      Flaherty ML, Haverbusch M, Kissela B, et al. Perimesencephalic subarachnoid hemorrhage: incidence, risk factors, and outcome. J Stroke Cerebrovasc Dis 2005; 14:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/9\">",
"      Lang EW, Khodair A, Barth H, et al. Subarachnoid hemorrhage of unknown origin and the basilar artery configuration. J Clin Neurosci 2003; 10:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/10\">",
"      Urbach H, Zentner J, Solymosi L. The need for repeat angiography in subarachnoid haemorrhage. Neuroradiology 1998; 40:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/11\">",
"      Hui FK, Tumial&aacute;n LM, Tanaka T, et al. Clinical differences between angiographically negative, diffuse subarachnoid hemorrhage and perimesencephalic subarachnoid hemorrhage. Neurocrit Care 2009; 11:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/12\">",
"      Marquardt G, Niebauer T, Schick U, Lorenz R. Long term follow up after perimesencephalic subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2000; 69:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/13\">",
"      Franz G, Brenneis C, Kampfl A, et al. Prognostic value of intraventricular blood in perimesencephalic nonaneurysmal subarachnoid hemorrhage. J Comput Assist Tomogr 2001; 25:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/14\">",
"      Ildan F, Tuna M, Erman T, et al. Prognosis and prognostic factors in nonaneurysmal perimesencephalic hemorrhage: a follow-up study in 29 patients. Surg Neurol 2002; 57:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/15\">",
"      Schievink WI, Wijdicks EF, Piepgras DG, et al. Perimesencephalic subarachnoid hemorrhage. Additional perspectives from four cases. Stroke 1994; 25:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/16\">",
"      Anderson RC, Baskin J, Feldstein N. Perimesencephalic nonaneurysmal subarachnoid hemorrhage in the pediatric population: case report and review of the literature. Pediatr Neurosurg 2002; 37:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/17\">",
"      Canh&atilde;o P, Falc&atilde;o F, Pinho e Melo T, et al. Vascular risk factors for perimesencephalic nonaneurysmal subarachnoid hemorrhage. J Neurol 1999; 246:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/18\">",
"      Kleinpeter G, Lehr S. Characterization of risk factor differences in perimesencephalic subarachnoid hemorrhage. Minim Invasive Neurosurg 2003; 46:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/19\">",
"      Tieleman AA, van der Vliet TA, Vos PE. Two first-degree relatives with perimesencephalic nonaneurysmal hemorrhage. Neurology 2006; 67:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/20\">",
"      Ruigrok YM, Rinkel GJ, Buskens E, et al. Perimesencephalic hemorrhage and CT angiography: A decision analysis. Stroke 2000; 31:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/21\">",
"      Velthuis BK, Rinkel GJ, Ramos LM, et al. Perimesencephalic hemorrhage. Exclusion of vertebrobasilar aneurysms with CT angiography. Stroke 1999; 30:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/22\">",
"      Pinto AN, Ferro JM, Canh&atilde;o P, Campos J. How often is a perimesencephalic subarachnoid haemorrhage CT pattern caused by ruptured aneurysms? Acta Neurochir (Wien) 1993; 124:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/23\">",
"      Al&eacute;n JF, Lagares A, Lobato RD, et al. Comparison between perimesencephalic nonaneurysmal subarachnoid hemorrhage and subarachnoid hemorrhage caused by posterior circulation aneurysms. J Neurosurg 2003; 98:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/24\">",
"      Kallmes DF, Clark HP, Dix JE, et al. Ruptured vertebrobasilar aneurysms: frequency of the nonaneurysmal perimesencephalic pattern of hemorrhage on CT scans. Radiology 1996; 201:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/25\">",
"      White JB, Wijdicks EF, Cloft HJ, Kallmes DF. Vanishing aneurysm in pretruncal nonaneurysmal subarachnoid hemorrhage. Neurology 2008; 71:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/26\">",
"      Schievink WI, Wijdicks EF. Origin of pretruncal nonaneurysmal subarachnoid hemorrhage: ruptured vein, perforating artery, or intramural hematoma? Mayo Clin Proc 2000; 75:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/27\">",
"      Alexander MS, Dias PS, Uttley D. Spontaneous subarachnoid hemorrhage and negative cerebral panangiography. Review of 140 cases. J Neurosurg 1986; 64:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/28\">",
"      Hochberg FH, Fisher CM, Roberson GH. Subarachnoid hemorrhage caused by rupture of a small superficial artery. Neurology 1974; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/29\">",
"      Rogg JM, Smeaton S, Doberstein C, et al. Assessment of the value of MR imaging for examining patients with angiographically negative subarachnoid hemorrhage. AJR Am J Roentgenol 1999; 172:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/30\">",
"      Tatter SB, Buonanno FS, Ogilvy CS. Acute lacunar stroke in association with angiogram-negative subarachnoid hemorrhage. Mechanistic implications of two cases. Stroke 1995; 26:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/31\">",
"      Matsuyama T, Okuchi K, Seki T, et al. Perimesencephalic nonaneurysmal subarachnoid hemorrhage caused by physical exertion. Neurol Med Chir (Tokyo) 2006; 46:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/32\">",
"      Watanabe A, Hirano K, Kamada M, et al. Perimesencephalic nonaneurysmal subarachnoid haemorrhage and variations in the veins. Neuroradiology 2002; 44:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/33\">",
"      van der Schaaf IC, Velthuis BK, Gouw A, Rinkel GJ. Venous drainage in perimesencephalic hemorrhage. Stroke 2004; 35:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/34\">",
"      Mathews MS, Brown D, Brant-Zawadzki M. Perimesencephalic nonaneurysmal hemorrhage associated with vein of Galen stenosis. Neurology 2008; 70:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/35\">",
"      Lee J, Koh EM, Chung CS, et al. Underlying venous pathology causing perimesencephalic subarachnoid hemorrhage. Can J Neurol Sci 2009; 36:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/36\">",
"      Matsumaru Y, Yanaka K, Muroi A, et al. Significance of a small bulge on the basilar artery in patients with perimesencephalic nonaneurysmal subarachnoid hemorrhage. Report of two cases. J Neurosurg 2003; 98:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/37\">",
"      Hashimoto H, Iida J, Shin Y, et al. Spinal dural arteriovenous fistula with perimesencephalic subarachnoid haemorrhage. J Clin Neurosci 2000; 7:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/38\">",
"      Wijdicks EF, Schievink WI. Perimesencephalic nonaneurysmal subarachnoid hemorrhage: first hint of a cause? Neurology 1997; 49:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/39\">",
"      Yaghi S, Oomman S, Keyrouz SG. Non-aneurysmal perimesencephalic subarachnoid hemorrhage caused by a cavernous angioma. Neurocrit Care 2011; 14:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/40\">",
"      Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg 1988; 68:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/41\">",
"      Caroscio JT, Brannan T, Budabin M, et al. Subarachnoid hemorrhage secondary to spinal arteriovenous malformation and aneurysm. Report of a case and review of the literature. Arch Neurol 1980; 37:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/42\">",
"      Hop JW, Brilstra EH, Rinkel GJ. Transient amnesia after perimesencephalic haemorrhage: the role of enlarged temporal horns. J Neurol Neurosurg Psychiatry 1998; 65:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/43\">",
"      Vermeer SE, Rinkel GJ, Algra A. Circadian fluctuations in onset of subarachnoid hemorrhage. New data on aneurysmal and perimesencephalic hemorrhage and a systematic review. Stroke 1997; 28:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/44\">",
"      Schievink WI, Wijdicks EF. Pretruncal subarachnoid hemorrhage: an anatomically correct description of the perimesencephalic subarachnoid hemorrhage. Stroke 1997; 28:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/45\">",
"      Schwartz TH, Mayer SA. Quadrigeminal variant of perimesencephalic nonaneurysmal subarachnoid hemorrhage. Neurosurgery 2000; 46:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/46\">",
"      Schwartz TH, Farkas J. Quadrigeminal non-aneurysmal subarachnoid hemorrhage--a true variant of perimesencephalic subarachnoid hemorrhage. Case report. Clin Neurol Neurosurg 2003; 105:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/47\">",
"      Tatter SB, Crowell RM, Ogilvy CS. Aneurysmal and microaneurysmal \"angiogram-negative\" subarachnoid hemorrhage. Neurosurgery 1995; 37:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/48\">",
"      Cloft HJ, Joseph GJ, Dion JE. Risk of cerebral angiography in patients with subarachnoid hemorrhage, cerebral aneurysm, and arteriovenous malformation: a meta-analysis. Stroke 1999; 30:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/49\">",
"      Chappell ET, Moure FC, Good MC. Comparison of computed tomographic angiography with digital subtraction angiography in the diagnosis of cerebral aneurysms: a meta-analysis. Neurosurgery 2003; 52:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/50\">",
"      Colen TW, Wang LC, Ghodke BV, et al. Effectiveness of MDCT angiography for the detection of intracranial aneurysms in patients with nontraumatic subarchnoid hemorrhage. AJR Am J Roentgenol 2007; 189:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/51\">",
"      van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007; 369:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/52\">",
"      Menke J, Larsen J, Kallenberg K. Diagnosing cerebral aneurysms by computed tomographic angiography: meta-analysis. Ann Neurol 2011; 69:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/53\">",
"      Westerlaan HE, van Dijk JM, van Dijk MJ, et al. Intracranial aneurysms in patients with subarachnoid hemorrhage: CT angiography as a primary examination tool for diagnosis--systematic review and meta-analysis. Radiology 2011; 258:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/54\">",
"      Kershenovich A, Rappaport ZH, Maimon S. Brain computed tomography angiographic scans as the sole diagnostic examination for excluding aneurysms in patients with perimesencephalic subarachnoid hemorrhage. Neurosurgery 2006; 59:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/55\">",
"      Topcuoglu MA, Ogilvy CS, Carter BS, et al. Subarachnoid hemorrhage without evident cause on initial angiography studies: diagnostic yield of subsequent angiography and other neuroimaging tests. J Neurosurg 2003; 98:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/56\">",
"      Huttner HB, Hartmann M, K&ouml;hrmann M, et al. Repeated digital substraction angiography after perimesencephalic subarachnoid hemorrhage? J Neuroradiol 2006; 33:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/57\">",
"      Hashimoto H, Iida J, Hironaka Y, et al. Use of spiral computerized tomography angiography in patients with subarachnoid hemorrhage in whom subtraction angiography did not reveal cerebral aneurysms. J Neurosurg 2000; 92:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/58\">",
"      Rinkel GJ, van Gijn J, Wijdicks EF. Subarachnoid hemorrhage without detectable aneurysm. A review of the causes. Stroke 1993; 24:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/59\">",
"      Wijdicks EF, Schievink WI, Miller GM. MR imaging in pretruncal nonaneurysmal subarachnoid hemorrhage: is it worthwhile? Stroke 1998; 29:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/60\">",
"      Rinkel GJ, Wijdicks EF, Vermeulen M, et al. The clinical course of perimesencephalic nonaneurysmal subarachnoid hemorrhage. Ann Neurol 1991; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/61\">",
"      Goergen SK, Barrie D, Sacharias N, Waugh JR. Perimesencephalic subarachnoid haemorrhage: negative angiography and favourable prognosis. Australas Radiol 1993; 37:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/62\">",
"      Greebe P, Rinkel GJ. Life expectancy after perimesencephalic subarachnoid hemorrhage. Stroke 2007; 38:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/63\">",
"      Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985; 16:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/64\">",
"      Sert A, Aydin K, Pirgon O, et al. Arterial spasm following perimesencephalic nonaneurysmal subarachnoid hemorrhage in a pediatric patient. Pediatr Neurol 2005; 32:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/65\">",
"      Sheehan JM, Cloft H, Kassell NF. Symptomatic delayed arterial spasm following non-aneurysmal perimesencephalic subarachnoid hemorrhage: a case report and review of the literature. Acta Neurochir (Wien) 2000; 142:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/66\">",
"      Schievink WI, Wijdicks EF, Spetzler RF. Diffuse vasospasm after pretruncal nonaneurysmal subarachnoid hemorrhage. AJNR Am J Neuroradiol 2000; 21:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/67\">",
"      Sloan MA, Alexandrov AV, Tegeler CH, et al. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2004; 62:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/68\">",
"      Krejza J, Kochanowicz J, Mariak Z, et al. Middle cerebral artery spasm after subarachnoid hemorrhage: detection with transcranial color-coded duplex US. Radiology 2005; 236:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/69\">",
"      Rinkel GJ, Wijdicks EF, Vermeulen M, et al. Acute hydrocephalus in nonaneurysmal perimesencephalic hemorrhage: evidence of CSF block at the tentorial hiatus. Neurology 1992; 42:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/70\">",
"      Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; :CD000277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/71\">",
"      Langham J, Goldfrad C, Teasdale G, et al. Calcium channel blockers for acute traumatic brain injury. Cochrane Database Syst Rev 2003; :CD000565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/72\">",
"      Vergouwen MD, Vermeulen M, Roos YB. Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review. Lancet Neurol 2006; 5:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/73\">",
"      Rinkel GJ, Wijdicks EF, Vermeulen M, et al. Outcome in perimesencephalic (nonaneurysmal) subarachnoid hemorrhage: a follow-up study in 37 patients. Neurology 1990; 40:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/74\">",
"      Madureira S, Canh&atilde;o P, Guerreiro M, Ferro JM. Cognitive and emotional consequences of perimesencephalic subarachnoid hemorrhage. J Neurol 2000; 247:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/75\">",
"      Greebe P, Rinkel GJ, Algra A. Anosmia after perimesencephalic nonaneurysmal hemorrhage. Stroke 2009; 40:2885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/18/6441/abstract/76\">",
"      Brilstra EH, Hop JW, Rinkel GJ. Quality of life after perimesencephalic haemorrhage. J Neurol Neurosurg Psychiatry 1997; 63:382.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1114 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6441=[""].join("\n");
var outline_f6_18_6441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cerebral angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Choice of first test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Repeated testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LONG-TERM PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31890620\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1114\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1114|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/12/41158\" title=\"diagnostic image 1\">",
"      CT perimesencephalic nonaneursymal SAH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1114|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/9/39063\" title=\"figure 1\">",
"      Subarachnoid spaces and cisterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1114|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/57/9115\" title=\"table 1\">",
"      Hunt and Hess grading system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=related_link\">",
"      Cerebral salt-wasting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=related_link\">",
"      Nonaneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_18_6442="Dexamethasone (systemic): Pediatric drug information";
var content_f6_18_6442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexamethasone (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14042?source=see_link\">",
"    see \"Dexamethasone (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41686?source=see_link\">",
"    see \"Dexamethasone (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8015648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Baycadron&trade;;",
"     </li>",
"     <li>",
"      Dexamethasone Intensol&trade;;",
"     </li>",
"     <li>",
"      DexPak&reg; 10 Day TaperPak&reg;;",
"     </li>",
"     <li>",
"      DexPak&reg; 13 Day TaperPak&reg;;",
"     </li>",
"     <li>",
"      DexPak&reg; 6 Day TaperPak&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8015649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dexamethasone&reg;;",
"     </li>",
"     <li>",
"      Dexasone&reg;;",
"     </li>",
"     <li>",
"      Dom-Dexamethasone;",
"     </li>",
"     <li>",
"      PHL-Dexamethasone;",
"     </li>",
"     <li>",
"      PMS-Dexamethasone;",
"     </li>",
"     <li>",
"      PRO-Dexamethasone;",
"     </li>",
"     <li>",
"      ratio-Dexamethasone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10473457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Airway edema or extubation:",
"     </b>",
"     I.V.: 0.25 mg/kg/dose given ~4 hours prior to scheduled extubation then every 8 hours for a total of 3 doses (Couser, 1992); others have used 0.5 mg/kg/dose every 8 hours for 3 doses with last dose administered 1 hour prior to scheduled extubation (Davis, 2001); range: 0.25-0.5 mg/kg/dose for 1-3 doses; maximum dose: 1.5 mg/kg/day; limited data available, reported dosing regimens variable.",
"     <b>",
"      Note:",
"     </b>",
"     A longer duration of therapy may be needed with more severe cases. A recent meta-analysis concluded that future neonatal clinical trials should study a multiple dose strategy with initiation of dexamethasone at least 12 hours before extubation (Khemani, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchopulmonary dysplasia, facilitation of ventilator wean:",
"     </b>",
"     PNA &ge;7 days: Oral, I.V.: Initial: 0.15 mg/kg/day given in divided doses every 12 hours for 3 days, then tapered every 3 days over 7 days; total dexamethasone dose: 0.89 mg/kg given over 10 days (Doyle, 2006); others have used 0.2 mg/kg/day given once daily and tapered every 3 days over 7 days (total dexamethasone dose: 1 mg/kg) (Durand, 2002) or tapered over 14 days (total dexamethasone dose: 1.9 mg/kg) (Whalther, 2003).",
"     <b>",
"      Note:",
"     </b>",
"     High doses (~0.5 mg/kg/day) do not confer additional benefit over lower doses, are associated with higher incidence of adverse effects (including adverse neurodevelopmental outcomes), and are not recommended for use (Watterberg, 2010). However, a meta-analysis reported total cumulative doses &gt;4 mg/kg reduced the relative risk for the combined outcome, mortality, or bronchopulmonary dysplasia; further studies are needed (Onland, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10473887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14042?source=see_link\">",
"      see \"Dexamethasone (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infants and Children:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute  mountain sickness (AMS) (moderate)/high altitude cerebral edema (HACE); treatment:",
"     </b>",
"     Oral, I.M., I.V.: 0.15 mg/kg/dose every 6 hours; consider using for high altitude pulmonary edema because of associated HACE with this condition (Luks, 2010; Pollard, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Airway edema or extubation:",
"     </b>",
"     Oral, I.M., I.V.: 0.5 mg/kg/dose given at 6-12 hours prior to extubation then every 6 hours for 6 doses (total dexamethasone dose: 3 mg/kg); maximum dose: 10 mg (Anene, 1996; Khemani, 2009; Tellez, 1991)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiemetic (chemotherapy-induced)",
"     </b>",
"     : Refer to individual protocols and emetogenic potential: I.V.: Severely emetogenic chemotherapy: Usual: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily on days of chemotherapy; some patients may require every 12 hour dosing; usual range: 8-14 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (Holdsworth, 2006; Jordan, 2010; Phillips, 2010); others have used: Initial: 10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 20 mg) then 5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory:",
"     </b>",
"     Oral, I.M., I.V.: 0.08-0.3 mg/kg/day or 2.5-10 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Asthma exacerbation:",
"     </b>",
"     Oral, I.M., I.V.: 0.6 mg/kg once (maximum dose: 16 mg) (Hegenbarth, 2008 )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bacterial meningitis (",
"      <i>",
"       H. influenzae",
"      </i>",
"      type b):",
"     </b>",
"     Infants and Children &gt;6 weeks: I.V.: 0.15 mg/kg/dose every 6 hours for the first 2-4 days of antibiotic treatment; start dexamethasone 10-20 minutes before or with the first dose of antibiotic; if antibiotics have already been administered, dexamethasone use has not been shown to improve patient outcome and is not recommended (Tunkel, 2004).",
"     <b>",
"      Note:",
"     </b>",
"     For pneumococcal meningitis, data has not shown clear benefit from dexamethasone administration; risk and benefits should be considered prior to use (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cerebral edema:",
"     </b>",
"     Oral, I.M., I.V.: Loading dose: 1-2 mg/kg/dose as a single dose; maintenance: 1-1.5 mg/kg/day (maximum dose: 16 mg/day) in divided doses every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Croup (laryngotracheobronchitis):",
"     </b>",
"     Oral, I.M., I.V.: 0.6 mg/kg once; usual maximum dose: 16 mg (doses as high as 20 mg have been used) (Bjornson, 2004; Hegenbarth, 2008; Rittichier, 2000);",
"     <b>",
"      Note:",
"     </b>",
"     A single oral dose of 0.15 mg/kg has been shown effective in children with mild to moderate croup (Russell, 2004; Sparrow, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Physiologic replacement:",
"     </b>",
"     Oral, I.M., I.V.: 0.03-0.15 mg/kg/day or 0.6-0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adults:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute mountain sickness (AMS)/high altitude cerebral edema (HACE):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention: Oral: 2 mg every 6 hours or 4 mg every 12 hours starting on the day of ascent; may be discontinued after staying at the same elevation for 2-3 days or if descent is initiated; do not exceed a 10-day duration (Luks, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     In situations of rapid ascent to altitudes &gt;3500 meters (such as rescue or military operations), 4 mg every 6 hours may be considered (Luks, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Oral, I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     AMS: 4 mg every 6 hours (Luks, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     HACE: Initial: 8 mg as a single dose; Maintenance: 4 mg every 6 hours until symptoms resolve (Luks, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral, I.M., I.V.: 0.75-9 mg/day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intra-articular, intralesional, or soft tissue: 0.4-6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Extubation or airway edema:",
"     </b>",
"     Oral, I.M., I.V.: 0.5-2 mg/kg/day in divided doses every 6 hours beginning 24 hours prior to extubation and continuing for 4-6 doses afterwards",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiemetic:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: Oral, I.V.: 10-20 mg 15-30 minutes before treatment on each treatment day; continuous infusion regimen: Oral or I.V.: 10 mg every 12 hours on each treatment day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Mildly emetogenic therapy: Oral, I.M., I.V.: 4 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Delayed nausea/vomiting: Oral: 4-10 mg 1-2 times/day for 2-4 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     8 mg every 12 hours for 2 days; then",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     4 mg every 12 hours for 2 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     20 mg 1 hour before chemotherapy; then",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     10 mg 12 hours after chemotherapy; then",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     8 mg every 12 hours for 4 doses; then",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     4 mg every 12 hours for 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Multiple myeloma:",
"     </b>",
"     Oral, I.V.: 40 mg/day, days 1-4, 9-12, and 17-20, repeated every 4 weeks (alone or as part of a regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cerebral edema:",
"     </b>",
"     I.V.: 10 mg stat, then 4 mg I.M./I.V. (should be given as sodium phosphate) every 6 hours until response is maximized, then switch to oral regimen, then taper off if appropriate; dosage may be reduced after 2-4 days and gradually discontinued over 5-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cushing's syndrome, diagnostic:",
"     </b>",
"     Oral: 1 mg at 11 PM, draw blood at 8 AM; greater accuracy for Cushing's syndrome may be achieved by the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dexamethasone: 0.5 mg by mouth every 6 hours for 48 hours (with 24-hour urine collection for 17-hydroxycorticosteroid excretion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Differentiation of Cushing's syndrome due to ACTH excess from Cushing's due to other causes: Oral: Dexamethasone 2 mg every 6 hours for 48 hours (with 24-hour urine collection for 17-hydroxycorticosteroid excretion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis (acute exacerbation):",
"     </b>",
"     Oral: 30 mg/day for 1 week, followed by 4-12 mg/day for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Shock, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Addisonian crisis/shock (eg, adrenal insufficiency/responsive to steroid therapy): I.V.: 4-10 mg as a single dose, which may be repeated if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unresponsive shock (eg, unresponsive to steroid therapy): I.V.: 1-6 mg/kg as a single I.V. dose or up to 40 mg initially followed by repeat doses every 2-6 hours while shock persists",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Physiological replacement:",
"     </b>",
"     Oral, I.M., I.V. (should be given as sodium phosphate): 0.03-0.15 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     0.6-0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8016329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral: 0.5 mg/5 mL (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baycadron&trade;: 0.5 mg/5 mL (237 mL) [contains benzoic acid, ethanol 5.1%, propylene glycol; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium phosphate: 4 mg/mL (1 mL, 5 mL, 30 mL); 10 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium phosphate [preservative free]: 10 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 0.5 mg/5 mL (240 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dexamethasone Intensol&trade;: 1 mg/mL (30 mL) [dye free, sugar free; contains benzoic acid, ethanol 30%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DexPak&reg; 6 Day TaperPak&reg;: 1.5 mg [scored; 21 tablets on taper dose card]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DexPak&reg; 10 Day TaperPak&reg;: 1.5 mg [scored; 35 tablets on taper dose card]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DexPak&reg; 13 Day TaperPak&reg;: 1.5 mg [scored; 51 tablets on taper dose card]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8015651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes concentrated oral solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10476979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with food or milk to decrease GI adverse effects; in some pediatric croup trials, dose was prepared using a parenteral dexamethasone formulation and mixing it with an oral flavored syrup (Bjornson, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: For doses &lt;10 mg, administer undiluted solution (4 mg/mL) I.V. push over 1-4 minutes; high-dose therapy must be diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS and administered by I.V. intermittent infusion over 15-30 minutes; pH: 7.0-8.5",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8015720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, allopurinol, amifostine, amikacin, amphotericin B cholesteryl sulfate complex, amsacrine, anidulafungin, aztreonam, bivalirudin, caffeine citrate, cefepime, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doripenem, doxorubicin, doxorubicin liposome, etoposide phosphate, famotidine, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, gallium nitrate, gemcitabine, granisetron, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactate electrolyte injection (Hextend&reg;), levofloxacin, linezolid, lorazepam, melphalan, meperidine, meropenem, methadone, milrinone, ondansetron, oxaliplatin, paclitaxel, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, sargramostim, sodium bicarbonate, sufentanil, tacrolimus, telavancin, teniposide, theophylline, thiotepa, vinorelbine, vitamin B complex with C, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ciprofloxacin, diphenhydramine, fenoldopam, fosaprepitant, haloperidol, idarubicin, midazolam, pantoprazole, topotecan.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydromorphone, methotrexate, metoclopramide, morphine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, dimenhydrinate, droperidol, furosemide, granisetron, ketamine, ketorolac, metoclopramide, palonosetron, ranitidine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, famotidine, glycopyrrolate, pantoprazole, promethazine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diphenhydramine, hydromorphone, midazolam, ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10473765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elixir: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); avoid freezing; dispense in tightly closed container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and freezing; dilution with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS is stable for at least 24 hours at room temperature or 2 days under refrigeration temperature (4&deg;C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral concentrated solution (Intensol&trade;): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze; do not use if precipitate is present; dispense only in original bottle and only with manufacturer-supplied calibrated dropper; discard open bottle after 90 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); dispense in tightly closed, light-resistant container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from moisture; dispense in tightly closed, light-resistant container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10473616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, parenteral: Primarily as an anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases, including those of allergic, hematologic, dermatologic, neoplastic, rheumatic, autoimmune, nervous system, renal, and respiratory origin [FDA approved in pediatric patients (age not specified) and adults]; primary or secondary adrenocorticoid deficiency (not first line) [FDA approved in pediatric patients (age not specified) and adults]; management of cerebral edema, shock, and as a diagnostic agent [FDA approved in pediatric patients (age not specified) and adults]. Has also been used as adjunctive antiemetic agent in the treatment of chemotherapy-induced emesis, treatment of croup (laryngotracheobronchitis), treatment of airway edema prior to extubation, treatment of acute mountain sickness (AMS) and high altitude cerebral edema (HACE), and in neonates with bronchopulmonary dysplasia to facilitate ventilator weaning",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8015647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexamethasone may be confused with desoximetasone, dextroamphetamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Decadron&reg; may be confused with Percodan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8015708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, cardiac arrest, cardiomyopathy, CHF, circulatory collapse, edema, hypertension, myocardial rupture (post-MI), syncope, thromboembolism, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, emotional instability, euphoria, headache, intracranial pressure increased, insomnia, malaise, mood swings, neuritis, personality changes, pseudotumor cerebri (usually following discontinuation), psychic disorders, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, allergic dermatitis, alopecia, angioedema, bruising, dry skin, erythema, fragile skin, hirsutism, hyper-/hypopigmentation, hypertrichosis, perianal pruritus (following I.V. injection), petechiae, rash, skin atrophy, skin test reaction impaired, striae, urticaria, wound healing impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal suppression, carbohydrate tolerance decreased, Cushing's syndrome, diabetes mellitus, glucose intolerance decreased, growth suppression (children), hyperglycemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary-adrenal axis suppression, protein catabolism, sodium retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, appetite increased, gastrointestinal hemorrhage, gastrointestinal perforation, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Altered (increased or decreased) spermatogenesis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatomegaly, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Postinjection flare (intra-articular use), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthropathy, aseptic necrosis (femoral and humoral heads), fractures, muscle mass loss, myopathy (particularly in conjunction with neuromuscular disease or neuromuscular-blocking agents), neuropathy, osteoporosis, parasthesia, tendon rupture, vertebral compression fractures, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmos, glaucoma, intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glucosuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abnormal fat deposition, anaphylactoid reaction, anaphylaxis, avascular necrosis, diaphoresis, hiccups, hypersensitivity, impaired wound healing, infections, Kaposi's sarcoma, moon face, secondary malignancy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10473617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dexamethasone or any component, active untreated infections, systemic fungal infections, cerebral malaria",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10473619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Use with extreme caution in patients with respiratory tuberculosis or untreated systemic infections. Use  with caution in patients with hypertension, heart failure, or renal impairment; long-term use has been associated with fluid retention and hypertension. Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to risk of GI bleeding and perforation. High-dose corticosteroids should not be used for management of head injury; increased mortality was observed in patients receiving high-dose I.V. methylprednisolone. Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids. Use with caution in patients with hepatic impairment, including cirrhosis; enhanced pharmacologic effect due to decreased metabolism and long-term use has been associated with fluid retention. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture; hypertrophic cardiomyopathy has been reported in premature neonates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with diabetes; corticosteroids may alter glucose regulation leading to hyperglycemia. Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use, consider routine eye exams in chronic users. Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Use with caution in patients with thyroid dysfunction; changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones. Dexamethasone does not provide adequate mineralocorticoid activity in adrenal insufficiency (may be employed as a single dose while cortisol assays are performed). Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Use with caution in patients with thromboembolic tendencies or thrombophlebitis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10473618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be tapered slowly and carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.  In premature neonates, the use of high-dose dexamethasone (approximately &gt;0.5 mg/kg/day) for the prevention or treatment of BPD has been associated with adverse neurodevelopmental outcomes, including higher rates of cerebral palsy without additional clinical benefit over lower doses; current data does not support use  of high doses, further studies are needed (Watterberg, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Acute myopathy may occur with high doses, usually in patients with neuromuscular transmission disorders; myopathy may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed. Increased IOP may occur especially with prolonged use; in children, increased IOP has been shown to be dose-dependent and produce a greater IOP in children &lt;6 years than older children (Lam, 2005).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Rare cases of anaphylactoid reactions have been reported with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Injection may contain sulfites and 0.5 mg tablet may contain tartrazine, either may cause allergic reactions in susceptible individuals. Concentrated oral solution (Intensol&trade;) and elixir may contain ethanol (30% and 5.1%, respectively). Concentrated oral solution (Intensol&trade;) and elixir contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates. Elixir may contain benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use dexamethasone products containing benzoic acid with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8015710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     P-glycoprotein;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2A6 (weak/moderate), CYP2B6 (weak/moderate), CYP2C9 (weak/moderate), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8015711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asparaginase (E. coli): May increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asparaginase (Erwinia): May increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: Dexamethasone (Systemic) may decrease the serum concentration of Cobicistat.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). Dexamethasone (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Dexamethasone (Systemic) may decrease the serum concentration of Elvitegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lenalidomide: Dexamethasone (Systemic) may enhance the thrombogenic effect of Lenalidomide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Dexamethasone (Systemic) may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thalidomide: Dexamethasone (Systemic) may enhance the dermatologic adverse effect of Thalidomide. Dexamethasone (Systemic) may enhance the thrombogenic effect of Thalidomide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10473764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc, and phosphorus and decreased sodium",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8015698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8015699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Dexamethasone crosses the placenta; and is partially metabolized to an inactive metabolite by placental enzymes. Due to its positive effect on stimulating fetal lung maturation, the injection is often used in patients with premature labor (24-34 weeks gestation). Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Women exposed to dexamethasone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10477064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin, occult blood loss, blood pressure, serum potassium and glucose; IOP with systemic use &gt;6 weeks; weight and height in children",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10477065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dexamethasone suppression test: 8 AM cortisol &lt;6 mcg/100 mL in adults given dexamethasone 1 mg at 11 PM the previous night",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10473766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses normal immune response",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10473767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: Metabolic effects can last for 72 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10473768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extremely low birth-weight infants with BPD: 9.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 3 months to 16 years: 4.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Healthy adults: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Within 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: In urine and bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10477067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41686?source=see_link\">",
"      see \"Dexamethasone (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by prescriber. Take exactly as directed, do not increase dose or discontinue abruptly without consulting prescriber.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral: Take with or after meals. Avoid alcohol and limit intake of caffeine or stimulants. Prescriber may recommend increased dietary vitamins, minerals, or iron. If you have diabetes, monitor glucose levels closely (antidiabetic medication may need to be adjusted). Inform prescriber if you are experiencing greater-than-normal levels of stress (medication may need adjustment). You may be more susceptible to infection (avoid crowds and persons with contagious or infective conditions and do not have any vaccinations unless approved by prescriber). Avoid exposure to measles or chicken pox; advise physician immediately if exposed; notify physician if acute illness including fever or other signs of infection occurs. Some forms of this medication may cause GI upset (small frequent meals and frequent mouth care may help). Report promptly excessive nervousness or sleep disturbances; signs of infection (eg, sore throat, unhealed injuries); excessive growth of body hair or loss of skin color; vision changes; weight gain; swelling of face or extremities; respiratory difficulty; muscle weakness; tarry stool, persistent abdominal pain; worsening of condition or failure to improve. Inform physician you are taking corticosteroid prior to any surgery or with any injury.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10477068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic: Due to the long duration of effect (36-54 hours), alternate day dosing does not allow time for adrenal recovery between doses.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Dexamethasone Therapy for Bacterial Meningitis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(1):130-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/2193301/pubmed\" id=\"2193301\" target=\"_blank\">",
"        2193301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anene O, Meert KL, Uy H, et al, \"Dexamethasone for the Prevention of Postextubation Airway Obstruction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1996, 24(10):1666-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/8874303/pubmed\" id=\"8874303\" target=\"_blank\">",
"        8874303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bjornson CL, Klassen TP, Williamson J, et al, \"A Randomized Trial of a Single Dose of Oral Dexamethasone for Mild Croup,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(13):1306-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/15385657/pubmed\" id=\"15385657\" target=\"_blank\">",
"        15385657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Couser RJ, Ferrara TB, Falde B, et al, &ldquo;Effectiveness of Dexamethasone in Preventing Extubation Failure in Preterm Infants at Increased Risk for Airway Edema,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 121(4):591-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/1403397/pubmed\" id=\"1403397\" target=\"_blank\">",
"        1403397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis PG and Henderson-Smart DJ, \"Intravenous Dexamethasone for Extubation of Newborn Infants,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2001, (4):CD000308.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/11687075/pubmed\" id=\"11687075\" target=\"_blank\">",
"        11687075",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doyle LW, Davis PG, Morley CJ, et al, \"Low-Dose Dexamethasone Facilitates Extubation Among Chronically Ventilator-Dependent Infants: A Multicenter, International, Randomized, Controlled Trial,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(1):75-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/16396863/pubmed\" id=\"16396863\" target=\"_blank\">",
"        16396863",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durand M, Mendoza ME, Tantivit P, et al, \"A Randomized Trial of Moderately Early Low-Dose Dexamethasone Therapy in Very Low Birth Weight Infants: Dynamic Pulmonary Mechanics, Oxygenation, and Ventilation,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 109(2):262-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/11826205/pubmed\" id=\"11826205\" target=\"_blank\">",
"        11826205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durand M, Sardesai S, and McEvoy C, &ldquo;Effects of Early Dexamethasone Therapy on Pulmonary Mechanics and Chronic Lung Disease in Very Low Birth Weight Infants: A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 95(4):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/7700763/pubmed\" id=\"7700763\" target=\"_blank\">",
"        7700763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holdsworth MT, Raisch DW, and Frost J, \"Acute and Delayed Nausea and Emesis Control in Pediatric Oncology Patients,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(4):931-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/16404740/pubmed\" id=\"16404740\" target=\"_blank\">",
"        16404740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jordan K, Roila F, Molassiotis A, et al, \"Antiemetics in Children Receiving Chemotherapy. MASCC/ESMO Guideline Update 2009,\"",
"      <i>",
"       Support Care Cancer",
"      </i>",
"      , 2010.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/20824481/pubmed\" id=\"20824481\" target=\"_blank\">",
"        20824481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khemani RG, Randolph A, and Markovitz B, \"Corticosteroids for the Prevention and Treatment of Post-Extubation Stridor in Neonates, Children and Adults,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2009, (3):CD001000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/19588321/pubmed\" id=\"19588321\" target=\"_blank\">",
"        19588321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kris MG, Hesketh PJ, Somerfield MR, et al, \"American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 2024(18):2932-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/16717289/pubmed\" id=\"16717289\" target=\"_blank\">",
"        16717289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, \"Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119 Suppl 2:S166-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/17332238/pubmed\" id=\"17332238\" target=\"_blank\">",
"        17332238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luks AM, McIntosh SE, Grissom CK, et al, \"Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness,\"",
"      <i>",
"       Wilderness Environ Med",
"      </i>",
"      , 2010, 21(2):146-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/20591379/pubmed\" id=\"20591379\" target=\"_blank\">",
"        20591379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mongelluzzo J, Mohamad Z, Ten Have TR, et al, \"Corticosteroids and Mortality in Children With Bacterial Meningitis,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 299(17):2048-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/18460665/pubmed\" id=\"18460665\" target=\"_blank\">",
"        18460665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Onland W, Offringa M, De Jaegere AP, et al, \"Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled Trials,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 123(1):367-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/19117904/pubmed\" id=\"19117904\" target=\"_blank\">",
"        19117904",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips RS, Gopaul S, Gibson F, et al, \"Antiemetic Medication for Prevention and Treatment of Chemotherapy Induced Nausea and Vomiting in Childhood,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, (9):CD007786.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/20824866/pubmed\" id=\"20824866\" target=\"_blank\">",
"        20824866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pollard AJ, Niermeyer S, Barry P, et al, \"Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,\"",
"      <i>",
"       High Alt Med Biol",
"      </i>",
"      , 2001, 2(3):389-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/11682018/pubmed\" id=\"11682018\" target=\"_blank\">",
"        11682018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rittichier KK and Ledwith CA, \"Outpatient Treatment of Moderate Croup With Dexamethasone: Intramuscular Versus Oral Dosing,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(6):1344-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/11099587/pubmed\" id=\"11099587\" target=\"_blank\">",
"        11099587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russell K, Wiebe N, Saenz A, et al, \"Glucocorticoids for Croup,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2004, (1):CD001955.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/14973975/pubmed\" id=\"14973975\" target=\"_blank\">",
"        14973975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sparrow A and Geelhoed G, \"Prednisolone Versus Dexamethasone in Croup: A Randomised Equivalence Trial,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2006, 91(7):580-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/16624882/pubmed\" id=\"16624882\" target=\"_blank\">",
"        16624882",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tellez DW, Galvis AG, Storgion SA, et al, \"Dexamethasone in the Prevention of Postextubation Stridor in Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 118(2):289-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/1993963/pubmed\" id=\"1993963\" target=\"_blank\">",
"        1993963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, \"Practice Guidelines for the Management of Bacterial Meningitis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van de Beek D, Farrar JJ, de Gans J, et al, \"Adjunctive Dexamethasone in Bacterial Meningitis: A Meta-analysis of Individual Patient Data,\"",
"      <i>",
"       Lancet Neurol",
"      </i>",
"      , 2010, 9(3):254-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/20138011/pubmed\" id=\"20138011\" target=\"_blank\">",
"        20138011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walther FJ, Findlay RD, and Durand M, \"Adrenal Suppression and Extubation Rate After Moderately Early Low-Dose Dexamethasone Therapy in Very Preterm Infants,\"",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2003, 74(1):37-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/14512180/pubmed\" id=\"14512180\" target=\"_blank\">",
"        14512180",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watterberg KL and American Academy of Pediatrics. Committee on Fetus and Newborn, \"Policy Statement--Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(4):800-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/18/6442/abstract-text/20819899/pubmed\" id=\"20819899\" target=\"_blank\">",
"        20819899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15964 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6442=[""].join("\n");
var outline_f6_18_6442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015648\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015649\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473457\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442279\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473887\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016329\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015651\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10476979\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015720\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473765\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473616\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015647\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015708\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473617\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473619\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473618\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015710\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015711\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473764\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015698\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015699\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10477064\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10477065\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473766\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473767\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10473768\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10477067\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10477068\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15964|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/997?source=related_link\">",
"      Dexamethasone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17172?source=related_link\">",
"      Dexamethasone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/51/5941?source=related_link\">",
"      Dexamethasone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14042?source=related_link\">",
"      Dexamethasone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/45/41686?source=related_link\">",
"      Dexamethasone (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_18_6443="Egg alternatives";
var content_f6_18_6443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F74067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F74067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutrients to be replaced on an egg avoidance diet and alternative dietary sources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Nutrients in egg",
"      </td>",
"      <td class=\"subtitle1\">",
"       Alternative dietary sources",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Protein",
"      </td>",
"      <td>",
"       Milk, soy, meat, fish, poultry, nuts, seeds, legumes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyanocobalamin (vitamin B12)",
"      </td>",
"      <td>",
"       Meat, fish, poultry, milk, enriched alternative \"milk\" beverages",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Selenium",
"      </td>",
"      <td>",
"       Brazil nut, beef, chicken, turkey, fish",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Riboflavin (vitamin B2)",
"      </td>",
"      <td>",
"       Milk, meat, enriched grains and cereals, dark green leafy vegetables",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Biotin",
"      </td>",
"      <td>",
"       Liver, soy, whole grains, green leafy vegetables",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pantothenic acid (vitamin B5)",
"      </td>",
"      <td>",
"       Milk, vegetables, whole grains, meat, fish, legumes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6443=[""].join("\n");
var outline_f6_18_6443=null;
var title_f6_18_6444="Spleen injury scale";
var content_f6_18_6444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spleen injury scale (1994 revision)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injury type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injury description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        I",
"       </td>",
"       <td>",
"        Hematoma",
"       </td>",
"       <td>",
"        Subcapsular, &lt;10 percent surface area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Capsular tear, &lt;1 cm parenchymal depth",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        II",
"       </td>",
"       <td>",
"        Hematoma",
"       </td>",
"       <td>",
"        Subcapsular, 10-50 percent surface area; intraparenchymal, &lt;5 cm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        1-3 cm parenchymal depth which does not involve a trabecular vessel",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        III",
"       </td>",
"       <td rowspan=\"2\">",
"        Hematoma",
"       </td>",
"       <td>",
"        Subcapsular, &gt;50 percent surface area or expanding; ruptured subcapsular or parenchymal hematoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraparenchymal hematoma &gt;5 cm or expanding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        &gt;3 cm parenchymal depth or involving trabecular vessels",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Laceration involving segmental or hilar vessels producing major devascularization (&gt;25 percent of spleen)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        V",
"       </td>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Completely shattered spleen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular",
"       </td>",
"       <td>",
"        Hilar vascular injury which devascularizes spleen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Advance one grade for multiple injuries, up to grade III.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Moore, EE, Cogbill, TH, Jurkovich, GJ, et al. Organ injury scaling: spleen and liver (1994 revision). J Trauma 1995; 38:323.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6444=[""].join("\n");
var outline_f6_18_6444=null;
var title_f6_18_6445="DDx of rash by appearance 3";
var content_f6_18_6445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of fever and rash based upon appearance of the rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Macules, papules, nodules, or plaques",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vesicles, bullae, or pustules",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purpuric macules, purpuric papules, or purpuric vesicles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Widespread erythema with or without edema followed by desquamation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Protozoal/parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Leishmania braziliensis",
"        </p>",
"        <p>",
"         Leishmania mexicana",
"        </p>",
"        <p>",
"         Leishmania tropica",
"        </p>",
"        <p>",
"         Necator americanus",
"        </p>",
"        <p>",
"         Onchocerca volvulus",
"        </p>",
"        <p>",
"         Schistosoma",
"        </p>",
"        <p>",
"         Strongyloides stercoralis",
"        </p>",
"        <p>",
"         Toxoplasma gondii (toxoplasmosis)",
"        </p>",
"        <p>",
"         Trichinella spiralis (trichinosis)",
"        </p>",
"        <p>",
"         Trypanosoma sp.",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Plasmodium falciparum (blackwater fever)*",
"        </p>",
"        <p>",
"         Trichinella spiralis (trichinosis)",
"        </p>",
"        <p>",
"         Toxoplasma gondii",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Noninfectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Erythema multiforme",
"        </p>",
"        <p>",
"         Systemic lupus erythematosus",
"        </p>",
"        <p>",
"         Dermatomyositis",
"        </p>",
"        <p>",
"         Drug hypersensitivities",
"        </p>",
"        <p>",
"         Gianotti-Crosti syndrome",
"        </p>",
"        <p>",
"         Inflammatory bowel disease",
"        </p>",
"        <p>",
"         Pityriasis rosea (fever rare)",
"        </p>",
"        <p>",
"         Sarcoidosis",
"        </p>",
"        <p>",
"         \"Serum sickness\"",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Sweet's syndrome (acute febrile neutrophilic dermatosis)",
"        </p>",
"        <p>",
"         Still's disease (juvenile idiopathic arthritis)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erythema multiforme bullosum",
"        </p>",
"        <p>",
"         Toxic epidermal necrolysis",
"        </p>",
"        <p>",
"         Dermatitis from plants",
"        </p>",
"        <p>",
"         Drug hypersensitivities",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         \"Allergic\" vasculitis",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Erythroderma",
"        </p>",
"        <p>",
"         Cholesterol embolization",
"        </p>",
"        <p>",
"         Disseminated intravascular coagulation (purpura fulminans)",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         Drug hypersensitivities",
"        </p>",
"        <p>",
"         Fat embolism",
"        </p>",
"        <p>",
"         Henoch-Sch&ouml;nlein purpura",
"        </p>",
"        <p>",
"         Immune thrombocytopenic purpura",
"        </p>",
"        <p>",
"         Granulomatosis with polyangiitis (Wegener's)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Erythroderma",
"        </p>",
"        <p>",
"         Drug hypersensitivities",
"        </p>",
"        <p>",
"         Graft-versus-host reaction",
"        </p>",
"        <p>",
"         Stevens-Johnson syndrome",
"        </p>",
"        <p>",
"         Toxic epidermal necrolysis",
"        </p>",
"        <p>",
"         von Zumbusch pustular psoriasis",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Reportable disease.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     May have arthralgia or musculoskeletal pain.",
"     <br/>",
"     &Delta; Often present as infarcts.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Sanders CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. Originally modified with permission from: Fitzpatrick TB, et al: Color Atlas &amp; Synopsis of Clinical Dermatology - Common and Serious Diseases. Fitzgerald TB, et al (Eds), McGraw-Hill, New York, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6445=[""].join("\n");
var outline_f6_18_6445=null;
var title_f6_18_6446="Drug effect on AV node";
var content_f6_18_6446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Effect of drugs on AV function in AF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 227px; background-image: url(data:image/gif;base64,R0lGODlhzQHjANUAAP////8AAAAAAIiIiERERLu7uyIiIt3d3REREZmZmWZmZjMzM+7u7szMzFVVVXd3d6qqqqCgoJ8AAICAgPDw8H8AABAQEP/u7g8AAO8AACAgIP93d/8REf+IiFBQUB8AADAwMMDAwNDQ0ODg4LCwsE8AAEBAQC8AAP+qqv9VVc8AAGBgYHBwcL8AAP/d3T8AAP/MzG8AAN8AAP+7u18AAP8iIv8zM5CQkP9ERK8AAP+ZmY8AAP9mZv/w8P/v7wAAACH5BAAAAAAALAAAAADNAeMAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxseSBQJiBANdzUQDBNHTS8rI2JENCwICBs5F1+HLWdBc5kLS1Ezi2e6KBwgK6Q5G7V/oWvnqQ/xK9+8C8lHg7UC0BUUOdBOwgMG1A9wEOLimoJqBBMoMCEDgoNuDIgMWNiAQcV6ChfMGGNDYUBk3BA0AFNAoIAGAfQYQMGSgroBO/wQ2IXabuKzBN6ECUjYTsG2owKdoGiz82G/eEYUQrjmoJnNZRSEXlRUAYGDaSSJSxwohME2ZQSEneRo4wACo2JvzgAKAgOAmuHQGGDD4pg6BswQIGGwdoszoWAfz4jVQOXYAQqiYzUj1GM1AkZELMS67yNirRdFrnd1L4HkINIUHEkQUcIBfWHIKFChcSHtfNQIKpMEWQpu0EGUIqNLsloDfgY4LbGaeDobgXCLx6gEYABkhg5pauV5TKdMuOWj30rp2BtvARwi0baMGkBuA3vXr4jWfZnh74sXHCeCTM5Ct0xl1CJpRQEQLDOCTN+AtgxRRABzAknmpdQWSSK/F1/+NRrWdJk59M33oVzQL1dPTT0FFRGED8iAVXzUhMZfgjTjmqOOOPPbo449ABilkjhAYEBN+AWJyjU9vWeHPkEEaAEER0Ag4Ho1cMdKMOE9S0SWUPcpmBDpXViLOd016mSWYPSpAFQAddeOMlbShpA5BzO2WZ0nb0bRARFMaoVBMyvD0YUw1GZBbaDfxeVI3KfkJqF/tNCjFAyKtuFEC3x0pBAKBsvkUAdKpZFCVBZS5XZYKXLZdQwVKZqpCznx1BHBwKgBjTA/UI1ERrd5Uj1SexjWrALVOsyU59P0FwKO82TiEAKEWdlhiDVqYAIyiYkaqEPWdSOeq6UwzgE7egNv/EFm87UdcZWsyhgBs0KYrYDroemZOTbItFOK75C47RHBSqJQUTwQMBwBtvSpQJHfdQuUmYIJ9s3Cqy1hWLlYAPOCZrbkaeK866hGx0jS7EnEvxx6fCJ+F780IsDoCC2EpFUBZ6x8DMHrmQH8RCyQmAAy8ZPG4MCZF84cGKLPQADL+ezG5X56kVo1JTX0T01vLud2HMk9Ns4PkoBlFXd00pOl9/b0c9FNSvrGAWuU462S8b+dNRJGeIpJPFUzqLfjghBdu+OF/fIn44pwoPk65jEfOiONEACT55XKUiCxSH6nEEgNfdzONxbBNSNM3bbHY5+eYty4G0HAOi0ABpta1/+3Io7NHG4AaktsfYnLRdZ/rxG+hMFnSkSofa5CTXpx0vQtHG3FSG1f89VjA7sCwAspHLJzKprS7eAKArvO5CIMFPfbsT/Hg5hF1fhp9abeVNm0TFu3N2jbJ1/7/AAygAAdIwAIa8IAITKACF8jABjrwgRCMoAQFQbk0WG6CrIjABDbIwQiM4A2YKlW8LljByjFLCecSwG8gdRydGMmEGGQFBYQQAQ18oAI4zGEJMAACFoRgDXVhC+ScUMLSMOEk0FMJA+Ixpf48wFW9i6EqQmBDCQTgiljEYgticAILeCACaEBM6ey0lLNASykmVAa0GnI6OKUNdEO4mRAcQJVmSP8FdPdwiTcQFRGbEIAmf9xImqQ4CQ1UIIuIRKQMJPABDYCxDAT4CDT4QZkoPqt8T1KGs7DCpXXJcWHoUhY4gCMOt5QmJttbmDPOdROz3MtihKREBD6QyFoikpGOHIOe0kXJalyjX92QWpIAABrmjIg3VvnUWPRDx9Tc0ZJc8sy93IKe89gtlo/QgBVtyc0r4vKRX9AY0UAlTn5cwz17Cdswg/Ud0ZhvXUaIFTkDw0T7OOOJMATAAuZxr5ZVM0PYjMQsu0lQbzYSnFyAJX0ckLTg+DJjYBNm7x6kEU5xw2eMGgLn1sLC8uzRhGkzyEKadiJx/K1bT4SjGywUqkRM4JD/BS0oI03ww1fciwgzRMYuqVLEW10zIfPKQk8tKS+VIuKlMU1qBTDggQ+24qYBGc6CtBOGiQkVb1GIziKQmtSYZiAGAmBBTgNaBeukSWF37MlyKhQ/mHWsIVXqYxHiRhZn1AUCeKqJTNbKOT3pJn6r28lDXCSEXhHnp4DgaldjKoMSWGACZKXCZgTwpgpN712F+YhWZFeA7FynSqtszbTeQh7yDAwhydFQKmFEu2qsdna1wxDv4FINZB1CsYuNaQteoAESRDYKk60sWjGZsOmdM3k2OUmgUPUs0VJPCHVZUP/yJdXRINd/N3EX8o5bhARgdRC4zW1MJYCBFYz1t0ww/yt2jLtP361yGasVkGdPNaexMM9koVJATpZIrY55pj8hiR0xu3eZ+LZWfeEpgmH1mUxCRKAE4s1tBnhbU/ROYZfgUMejNMJWj1iIQHCtb3OB9SZacdQbntmwhADb0I3KZ7BO0adNzGaIEWAgwuLdAQYga2EwmBYL8RjkEn7cBZ+ADgLfBQQIWoDj3KrgBCAQQY+3UKPZbSGlTKgy3bjA0kawIAZNFm8FLHCDKbsuBCcIs3hb8AETnNfMjLOADNQsYRpYwLdwfsJQ8YHYV3hgm3ReLHkRmmcUJnkMJzVCL0vx4ECLVwUYYEGhs3xoZvS5H5XuBAUEkAFHO/kDK5i0gv8zlbpNdYoIoEKM1xhDE6gB1nM7caOcFGJfz0yIjB7VC0k6iok/e1rCJ3CzqIlTLf5cq2hQuwi3InkE7XE2ts35LNTuxTzeLfp3iRGiKTHR6F8vdsIgeDOcDaYAhCmMYZB5WD0WpEJPHc84yjtNuJpB6xFbr5fnPkCHhDyJTXfa24ulgQakPGz7uAvAiekZnGAXsiE4e8AHRp4SBzMnP/qMK+U09s72rQlfA5ybFwAAB7IYAwsQHM5o2wn/PuUMtxHgUJVDl6s5Ix/9IcBiNVqArV3U0JVzPBPdxmIHhICDK4a8BkYHgA2aHPKRZ1ECFiB0wdnk7yy6QAg6uKIOALD/gQCkAAAwCHPTEznoqQfN414H+wUuMHIcgD0AKOB6Foc+g5Cj4IpDF0LXOTADAKxd5ByIOwBckIIAQJrHZmfTQK8Y9w00/opXx8HaETn0rofcBhsAQAcC0PcUPL7pcU9BDQZ/RUiHOvFsMsEhR0+EsAcg81fP+tzlDgOlhz4AQ+9A7Zfe9JATwekZOIF5UQ+lEGAgA5m/ewAiHwDWA6Dos+/67jO/+c53PgCgBwAPahn8cBN/SB6IwdULj3sAyL7vLkhk5QOw+/L7ves1uDoMmh54APjA74jMAA28/30gjUAAc/ZxOGZnJ9d/PcICECaAODZmBWiAOkIBFsBkChhh/1AndQ54IxPwAhOIYxIgABZ4gQiiTRtIgR4IgjpCAhigAiMoXh34gSaIGSxwAv+2gl3Vgi+IIyZAAzSYWzZ4gwgCgTuwg4JWgj5IHSIgACoohEnVg2YHVSeyBIkWBVhGBiXkhE4QOGVwA8enhEtIhA/kNKsGEpXmhFFIBGXoBEEmBlxyaFYYPXizZ1iwAhrIhePlhQ1kSqykaGO4ZWcIUGVVWV+whkvQhhdEBDRGBhQAAmBGhzIlAHhWQOpVGgZhWEihGyhxRkXAEDYySWkTE1gzErWyALUBc4niJiKBX3Ahc7YSSRmxEXHSOTmxE3rCRh8Ca+uSc4hSAKvoMbXYFv+tZjOX1gUiYAE5wIgyZXIFFFwgBSmKERkw0SVxoTKr1Bd2xBT0QQAl4xdfkTKG9SsL01KjtRYlhj+0cRdlcUl9UjF/wUnkAG3f8xXyRY4HIIgM1yxEkFfRwm9TgIJJaIzcVAH8J0DKKIlE4x7LURP8AEyXBTDUNAD3NRP3tRYIEFT1Ik1XoxHlpjJvwW7Y6BcPMA8mpRoZ8xu68nLG1I6n8ZAW6ZEgiZLHAy7B6AUTIIP+2E0l4AGQWBAmZBAUVyD9cBno5DbTMhb+NADfsxXZGEn6dQApM5RFMDxkAY4FMhMw0Tv/pA76wU4RYj6ncZTTME05QSjl415F8Elm4AH/CViT3HcCiJdAYCgRSzQbTKkTwRFRKvMhY8GJDOGJHFIrRoI1/DQWKQdP4FJHMKdPD5Uh45EiHlVR+oM66hM6C5CLNlMNj6kptnWIZ5CIMLVYNdB3fod03JR5TpdFF7B53QRpj1iEV5CGRhBdlOYFsElEmfYFw1iMXcUBLnABhed53USaiXSaBZUDyMiaWDCFRIBPsdkFytkEWLgG/NhVPGB+iOR7AKB8VwSc1YmaBAWQ4mac7jCTM0hQ61dLkccBRnB3eUcES2eTOAmeUIGWSZV5sid0REB+rydywcmdBBV8bblAcIgFfWgMnBlTusmbXocCmTcDcAcA+Kmdpsmf/wSlmg4UoFcwoPwwoLQwjIDWTZ8pBBdQAxxQexdQew+qn9u5WMT5nQZkoVaAobV5CyQgAB2qgOOZVDRgAgiEKd0wGaUGFKfmcC31iQ+ia3wia8hyFvQBkq2GEno5mY3Ca7MQATSqltz3AWVmQP0FOdiGbNrCLUOQjV2qbfEhbUpaH7CToUZpjV9BpvroClRao1YaAC1QnAREbuZ2WejmMN9AVSMmBPm2b/PmkLhhiU2ipip5Ii85pVU6p1kEkAmUMxqHPgr3M84iptPIAPs2cd/gFhCRF38hTtWISqJkWW/6CnHqqFnElgQ0mOlTpNLRNguZDiIBq4pKGzZnMS+HAP/t9T5GSZdPGhM/dwupqqqGhwEVBp8CUayqugMawKLKigzM6qgvcHrRuqyN6qgZgAGrea3uMK1WKgEa4K1PAa5q+QL/Sa7YYK7+WKfQqq7EwK7GWAKSBq/vIK90KAMC4FT2mg34yoUx8J796q/ZWpPbmqwDewz/KoQVoKMJS7Byyogf4IIPGwwLS4MS4LAVK60Fy4jbyq8bawwkYAGdaYw0kK4hOwwiAAIlcKNK2ALjSkBteAcuqgU12wgU4AEn0I90+AEIizkhZAQzGwUaejdtUESldEKNMAEYgJt0WAHW2jpBFC9DWwc3iwVIq7SRMLIlK4QyYAHvGjSROARiND3/MvIYb6RHVYmLHdOXCyNXlSgFqoYsK/dJdDS3zqI5M0dZgXWLC5E7pmo6eLliNLcSsVYIK9uydPgCFBsxA+kakkQgtUU7nkQ2eakrbPqVoQJafRIykqFR0YISZvgmOgM8hoUrMMFsRvBwrOWOuFNXpso7SStgrTsXtnMIObuzXCgBAks4j2tZI4U874KPCjAiCpCoeMpczHOQ6+Oc3ICN0vMWtMEXzbEAfCETz+tuCwlv2nUR96UOzqMtRqQh3Itdt9W0Svi1iDO2rwJdoGJglqFSxuuVqOZdIlZtDUYFkHE+iWEf83IufuqTLDcE8NuV1rgYuBISz0E+eARf3BNx/9ZzCCO7iDt4Aj+7OAqlAAzFEvcSJxECLuKzl66qvDvnL0R7KCsHPkSjVyb5QvIya682P3iyAPajiQeQPxcFY3xrvoiwsi/gsgoYA/WasgJBASuQgjTYAiBAxJhxAwIQhCuIASDLxO8wjDQAxN5WAo1LxcVAASaguxNYASjLxdnAAhgQsZ4mxmSMGSSgAS8ggQCnxmuMGRNgASUQgL8mx3MMFRTAAgIQA1i8gGO8x+4wAh6AAV0bZnpMyJgRAibwARIQyF01sYyMIBFgAhhAA3DMgjFbyQgyAhNgQxWAx5O8xWFQiE0wLp4MCSGwAhbwAhJAyt1UAQLQW1mwbW3aZ/+ozASqvMqQQAER4AEWcAIxsMm31Ega0A0m0IBSgMuVtsuDiDG+XAkhwAIggAElkEM5dFAAQAF13A3DRwXO7Bea2g19URoX1QD1xjy7ljVnq8P5O82MMAIaxEEbRGiG3A1kJs7RIkqFYg8H7ADrrC/2s8DvohXO2Dc3UrS0ebQxegwhAALdoAEXbA2Xlctty3DRNNC3Kr4Xc07twgo1Es+QFJNQkElaqwWqcrXAMEMRYAHd0FRQMM7oIBVNIg7txcL6ojvP8cAIHQssXQUM3QQoPQaLhiN9vBATELYEeY2UIrqlEVKSudOmahSaKM1RQwrsSy5vayN6Kw0KHCcNMYv/PENYNfJCHuwsFnNXeWUTmrMMmPgkbWSSBOAQmliVmrM+C5YOc1MnkGKLRjUdI2AC+mzKbNADq/C7XG1b5JGmJBW/+rSO1CJOxFSVvWIqTwgYnXta9qFZJ2QsWRJNgtEgd4G6NnG9Q3C9X+EAZMPV0JYjbazMFb0jis0P1DYXC8kPxFtMNfEcDJEAFTmohjg7WpVCBWFccC2XRb2k6VC8hbpLC/kdSPYAiNEAKz0/OvLNAhDOQLLVtl1r9oRpfK1SWplERlKVFENxwLJfLPNf70UWMSNR/8yprc3cUEkEP7MtE6khGReZO2LE+jzIQDLSU8M8vuoPHowRLoSQjAKY/7lqNybWNStxSRASOiDyJI/ZNXVtvHtlItHQv71aFHTJwzriyBPdrWZGZBj00so8xb+lZdjkzQshVvIsKvksAFFX46JCRd0AArN9OVW7BwMa5KJyAzAtADKNOLOrMls2B3KkwWMSk0QuKgCO40t9OKg85WtgWncV5bzc5IMjAoRdyy5+I3ob10uhb6IzGIPbYd3Ah4CkEUF1Og1QzhvRtj2KiWcra4RpiNTWF21NzibZF3R+MVB+E9QN1RHTxgGpI/V4SXJRGYGBbLMLIGToSmOhUPD9z8RmBHHhAJdBYKBjlgQcufeIEMsS2PD90bRh02Q7lkFDAWWeIMejkFITLv8D4NxJYhxkKJKpwQB5NQ+YAmAYyQC2zuu6iExIwBfDYdxUPewDAOyiey/N8JHPIpc6jgawE5RhQ9//vFkQZ4a+7hfR2F5C4OqfwhrxDb99PlufQsOWNSVFGaY1MZY5bV8TmenxHd7ZPgYHHlH+QNej7Q3XYNXcwIfjTm8RoShgWG7oojYRZdUagbY2YmWjljxcsyyQghSKojXnaOGt3r/9ntizKgRI5gYPYNIjzwlgqPIr//IwH/O1AM1HoOVsQPOnnNIyvwU4n4lg/g86H4hBTwY4P01Dv/OPEwU2vwY9L/Sp/PNI3+F69darosACr0cvpIl65WKG2xKmgWAQwhH/nBEFeKvDH7HXr9IU3giohHX1d00oa2UrpBEn8hAahMu3aqvQ06wX19sf4/HYk07aAa1KnftatGO7GCL3opHprrReoZs1kGtEhq/a08DalI3fGBf4losX4U0Rp4HZDOnAlY0xl5vt0F1dXI3rut65ty282fViX79d1kRUzttu3JVd0h1J1e3bWjUE1qP6xov6ih8uoe/6pMLhxtD0hqD8dQCVADaS6d2p5HDvI1bAYN+5PjEf/6S/um5gC6ff56zZBJz56sjhz4/9OXMdnQ7uaYH8nPDkfooEX5K1V5VlnejmzasEN0O8jQkEDcAQUBAQkUnlktl0PpUFg0BgACSo/4vjgEAkUAkMY/YAEBSu1oNW8ABwh4aEEXCYLhDzI4AwKO6hkL6qGujWqNzeEBgAFhTeqAQSkA4FHPjAxPYUHrEEtOru8jAFEAAUqLDq2NzoTh8DY2VnaWsHrAAYECCg4Gr/fpV8mxoEhAYWABwuIQQYn8b8kBjkABD8HpKJXIO7vb+3AcHHycvNz9HTZRnOrkwHqAyEPlMPIhX6CAzgpKgG8OPouXLvTR8BZYZwgedJgAJ7VByygTWkmZBiuniZQROoT5JbAC4CC6dFnhk2k/SBmYIAoTqXSLi9lDmTZk2btBy46dMAgZAHlwT4+eiLwIIycK4RAQhATkwsDG5tJP8SFclTXw4eHeiJxAEVBM7amZlEZIokJR2JaOXlykhLI0KWmRFqikAXLGj23dS7l29fv3+fQGB5kGEVjWkKDkHLxV7LpU2PJGBzcNjULlcmH/BVNtWSAaZ2DQkLBe2QpSFjuvrYrm1HV6UBx5Y9m3btQAgWdOEphEi7BFaQKZaGVNobKwXy0DHgppnmy0g2M6esDasT5H7iNntGungxqUmzwdzj6PADK673wLa9nn179y8fmIUE8fBvkF/xDe+C3J+dT8m3iIey5yxLSMADeGqokoOQQCWoISoZC5pIcCHgkm2+KikcMsyIBw30hHtPxBFJLNHEE385gwIUWWzRxRd8YbRttBhprNHGG3HMUccdeezRxx+BDFLIIYks0sgjkUxSySWZbNLJJ6GMUsopqazSyiuxzFLLLbns0ssvwQxTzDHJLNPMM9FMU8012WzTzTfhjFPOOems08478cxTzz357NPPPwENVNBBCS3U0EMRTVTRRRlt1NFHIQUsCAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Various drugs can slow conduction through the atrioventricular node in atrial fibrillation by altering its physiology. The calcium (Ca++) channel blockers, primarily diltiazem and verapamil, block the influx of calcium and therefore slow conduction by reducing the upstroke of the action potential; digoxin, carotid massage, Valsalva maneuver, and edrophonium are vagotonic and slow conduction by increasing parasympathetic effects on the node; beta blockers slow conduction by offsetting sympathetic inputs; and adenosine slows conduction only transiently by increasing potassium conduction and decreasing calcium influx.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6446=[""].join("\n");
var outline_f6_18_6446=null;
var title_f6_18_6447="Popliteal aneurysm on CT angiography";
var content_f6_18_6447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Popliteal aneurysm on CT angiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT angiogram demonstrates a large right popliteal artery aneurysm and tortuous distal superficial femoral artery. The true diameter of the aneurysm must be measured from cross-sectional two-dimensional images; this three-dimensional CT reconstruction shows only regions where intravenous contrast is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Amy B Reed, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_18_6447=[""].join("\n");
var outline_f6_18_6447=null;
